<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f3c17d88-383d-89de-d8d6-8ed1bb1b3750"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">
         <content styleCode="bold"/>
         <content styleCode="bold">These highlights do not include all the information needed to use LURASIDONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for LURASIDONE HYDROCHLORIDE TABLETS.<br/>
         </content>
      </content>
      <br/>
      <content styleCode="bold">LURASIDONE </content>
      <content styleCode="bold">
         <content styleCode="bold">
            <content styleCode="bold">
               <content styleCode="bold">HYDROCHLORIDE</content>
            </content> tablets, for oral useÂ  </content>
      </content>
      <br/>
      <content styleCode="bold">
         <content styleCode="bold">Initial U.S. Approval: 2010</content>
      </content>
   </title>
   <effectiveTime value="20250225"/>
   <setId root="9b512af1-98ab-1242-10e8-9534a002306e"/>
   <versionNumber value="13"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="802315887" root="1.3.6.1.4.1.519.1"/>
            <name>Dr. Reddys Laboratories Inc</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="860037244" root="1.3.6.1.4.1.519.1"/>
                        <name>Dr. Reddys Laboratories Limited (SEZ UNIT)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-351" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-351" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-352" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-352" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-353" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-353" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-354" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-354" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="7a472440-7042-f432-7144-2139b37b66cb"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250225"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="43598-351"/>
                        <name>Lurasidone hydrochloride</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lurasidone hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O0P4I5851I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LURASIDONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="22IC88528T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lurasidone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-351-30"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-351-90"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-351-05"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-351-79"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="43598-351-78"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230220"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230220"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA208047" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code codeSystem="1.0.3166.1.2.3" code="USA"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">351;20</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>white to off white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="43598-352"/>
                        <name>Lurasidone hydrochloride</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lurasidone hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O0P4I5851I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LURASIDONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="22IC88528T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lurasidone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-352-30"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-352-90"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-352-05"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-352-79"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="43598-352-78"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230220"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230220"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA208047" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code codeSystem="1.0.3166.1.2.3" code="USA"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">352;40</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>white to off white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="43598-353"/>
                        <name>Lurasidone hydrochloride</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lurasidone hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="60"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O0P4I5851I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LURASIDONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="22IC88528T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lurasidone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-353-30"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-353-90"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-353-05"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-353-79"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="43598-353-78"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230220"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230220"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA208047" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code codeSystem="1.0.3166.1.2.3" code="USA"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">353;60</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>white to off white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="43598-354"/>
                        <name>Lurasidone hydrochloride</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lurasidone hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="80"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O0P4I5851I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LURASIDONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="22IC88528T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lurasidone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-354-30"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-354-90"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-354-05"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-354-79"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="43598-354-78"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230220"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230220"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA208047" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code codeSystem="1.0.3166.1.2.3" code="USA"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" displayName="GREEN" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>pale green</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">354;80</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <section>
                     <id root="a581c24f-290f-507d-c0ef-783dda25d230"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <effectiveTime value="20141016"/>
                     <component>
                        <observationMedia ID="MM186808563982">
                           <text>structure </text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="structure.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM990045371314">
                           <text>figure1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM36275844619">
                           <text>figure2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM327435983319">
                           <text>figure3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM422040808245">
                           <text>container1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="container1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM990570970631">
                           <text>container2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="container2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM268515872403">
                           <text>container3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="container3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM595495744452">
                           <text>container4</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="container4.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM17033132784">
                           <text>carton1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="carton1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM309613880024">
                           <text>carton2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="carton2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM168384972006">
                           <text>carton3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="carton3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM692781031621">
                           <text>carton4</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="carton4.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="BOXED_WARNING">
               <id root="23d5d41e-de24-6319-1d53-a80673399841"/>
               <code code="34066-1" displayName="BOXED WARNING SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title> WARNING: INCREASEDÂ MORTALITYÂ INÂ ELDERLYÂ PATIENTSÂ WITHÂ DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS </title>
               <text>
                  <paragraph>
                     <content styleCode="bold underline">Increased Mortality in Elderly Patients with Dementia-Related Psychosis</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone hydrochloride tablets are not approved for the treatment of patients with dementia-related psychosis </content>
                     <content styleCode="bold italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_9a2c7fa4-f522-abb9-14e6-f251720c410d">5.1</linkHtml>
                     <content styleCode="bold italics">)].</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold underline">Suicidal Thoughts and Behaviors</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviorsÂ </content>
                     <content styleCode="bold italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_f4c6c181-4e79-9e4b-fac8-30b76b163a6c">5.2</linkHtml>
                     <content styleCode="bold italics">)]</content>
                     <content styleCode="bold">.</content>
                  </paragraph>
                  <br/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold"> WARNING</content>: <content styleCode="bold">INCREASEDÂ MORTALITYÂ INÂ ELDERLYÂ PATIENTSÂ WITH DEMENTIA-RELATED PSYCHOSIS;Â andÂ SUICIDALÂ THOUGHTS ANDÂ BEHAVIORS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">SeeÂ fullÂ prescribingÂ informationÂ forÂ completeÂ boxedÂ warning.</content>Â  </paragraph>
                        <paragraph> â¢ <content styleCode="bold"> ElderlyÂ patientsÂ withÂ dementia-relatedÂ psychosisÂ treated with antipsychoticÂ drugsÂ areÂ atÂ anÂ increasedÂ riskÂ ofÂ death. </content>
                           <content styleCode="bold">Lurasidone hydrochloride tablets are not approved for the treatment of patients with dementia-related psychosis (</content>
                           <content styleCode="bold">
                              <linkHtml href="#_9a2c7fa4-f522-abb9-14e6-f251720c410d">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">).</content>
                        </paragraph>
                        <paragraph> â¢ <content styleCode="bold">Â  Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients. Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors</content>
                           <content styleCode="bold"> (</content>
                           <content styleCode="bold">
                              <linkHtml href="#_f4c6c181-4e79-9e4b-fac8-30b76b163a6c">5.2</linkHtml>
                           </content>
                           <content styleCode="bold">).</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_cd1c03b5-e303-3cb9-cff2-b3cc7c606306">
               <id root="1921a0c4-c688-0fbe-fa49-bad80e04bea7"/>
               <code code="43683-2" displayName="RECENT MAJOR CHANGES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>RECENT MAJOR CHANGES SECTION</title>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions (<linkHtml href="#_bc1f52e9-67f4-8271-ff7e-e7cc04d8ec54">5.7</linkHtml>) 1/2025</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="INDICATIONS_AND_USAGE">
               <id root="0c963148-daa3-4082-38b9-07ce6374b097"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Lurasidone hydrochloride tablets are indicated for: Â  </paragraph>
                  <paragraph> â¢ Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) <content styleCode="italics">[see Clinical Studies (</content>
                     <linkHtml href="#_d711956a-c8d2-2fb5-6914-2fc9cce2952e">14.2</linkHtml>
                     <content styleCode="italics">)]</content>. Â  </paragraph>
                  <paragraph> â¢ Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) <content styleCode="italics">[see Clinical Studies (</content>
                     <linkHtml href="#_d711956a-c8d2-2fb5-6914-2fc9cce2952e">14.2</linkHtml>
                     <content styleCode="italics">)].</content> Â  </paragraph>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>LurasidoneÂ hydrochloride is anÂ atypicalÂ antipsychoticÂ indicated forÂ theÂ treatmentÂ of:</paragraph>
                        <list>
                           <item>DepressiveÂ <content>episode</content>Â associatedÂ withÂ BipolarÂ IÂ DisorderÂ (bipolar depression) in adultsÂ and pediatric patients (10 to 17 years) as monotherapyÂ Â (<linkHtml href="#INDICATIONS_AND_USAGE">1</linkHtml>,Â <linkHtml href="#_d711956a-c8d2-2fb5-6914-2fc9cce2952e">14.2</linkHtml>)</item>
                           <item>Â Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults as Â adjunctiveÂ therapyÂ withÂ lithiumÂ or valproateÂ (<linkHtml href="#INDICATIONS_AND_USAGE">1</linkHtml>,Â <linkHtml href="#_d711956a-c8d2-2fb5-6914-2fc9cce2952e">14.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="DOSAGE_AND_ADMINISTRATION">
               <id root="4e3ce311-c239-250b-f541-5877b7b68ce2"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lurasidone hydrochloride tabletsÂ shouldÂ beÂ takenÂ withÂ foodÂ (atÂ leastÂ 350Â calories).Â Administration with food substantially increases the absorption ofÂ lurasidone hydrochlorideÂ (<linkHtml href="#_b30d332c-3939-8af6-1706-567e2831f491">2.3</linkHtml>,Â <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>).</paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Indication</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">StartingÂ Dose</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">RecommendedÂ Dose</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> BipolarÂ Depression-adults <linkHtml href="#_fdd5ef0e-2ec4-12e4-3c30-8583c4ee8ae9">(2.2</linkHtml>)</td>
                                 <td> 20Â mgÂ perÂ day</td>
                                 <td> 20Â mgÂ toÂ 120Â mgÂ perÂ day</td>
                              </tr>
                              <tr>
                                 <td>Bipolar Depression-pediatric patients (10 to17 years) (<linkHtml href="#_fdd5ef0e-2ec4-12e4-3c30-8583c4ee8ae9">2.2</linkHtml>)</td>
                                 <td>20 mg per day</td>
                                 <td>20 mg to 80 mg per day</td>
                              </tr>
                           </tbody>
                        </table>
                        <list>
                           <item>
                              <content styleCode="underline">ModerateÂ andÂ SevereÂ RenalÂ Impairment</content>:Â RecommendedÂ starting doseÂ isÂ 20Â mgÂ perÂ day,Â andÂ the maximumÂ recommendedÂ doseÂ isÂ 80 mgÂ perÂ dayÂ (<linkHtml href="#_83721e04-563e-b6d4-eb60-19c19c0bf51f">2.4</linkHtml>,Â <linkHtml href="#_835b2b82-75f8-8a61-729c-d8c451263468">8.6</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">ModerateÂ andÂ SevereÂ HepaticÂ Impairment:</content>Â RecommendedÂ starting doseÂ isÂ 20Â mgÂ perÂ day.Â TheÂ maximumÂ recommendedÂ doseÂ isÂ 80Â mg perÂ dayÂ inÂ moderateÂ hepaticÂ impairmentÂ andÂ 40Â mgÂ perÂ dayÂ in severeÂ hepaticÂ impairmentÂ (<linkHtml href="#_83721e04-563e-b6d4-eb60-19c19c0bf51f">2.5</linkHtml>,Â <linkHtml href="#_835b2b82-75f8-8a61-729c-d8c451263468">8.7</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">ConcomitantÂ UseÂ ofÂ aÂ ModerateÂ CYP3A4Â inhibitorÂ (e.g., diltiazem)</content>: Lurasidone hydrochloride Â doseÂ shouldÂ beÂ reducedÂ toÂ halfÂ ofÂ the originalÂ doseÂ level.Â RecommendedÂ startingÂ doseÂ isÂ 20Â mgÂ perÂ day. MaximumÂ recommendedÂ doseÂ isÂ 80 mgÂ perÂ dayÂ (<linkHtml href="#_7816ac27-85cb-5181-8780-5bd594b8b4f1">2.6</linkHtml>,Â <linkHtml href="#_9033c447-94f5-8fa9-0509-3fa796995fe1">7.1</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">ConcomitantÂ UseÂ ofÂ aÂ ModerateÂ CYP3A4Â Inducer</content>: ItÂ mayÂ beÂ necessaryÂ toÂ increaseÂ theÂ doseÂ ofÂ lurasidone hydrochlorideÂ (<linkHtml href="#_7816ac27-85cb-5181-8780-5bd594b8b4f1">2.6</linkHtml>,Â <linkHtml href="#_9033c447-94f5-8fa9-0509-3fa796995fe1">7.1</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_fdd5ef0e-2ec4-12e4-3c30-8583c4ee8ae9">
                     <id root="cee7ed53-a96d-27b9-4e89-0f4f0536a78f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2  Depressive Episodes Associated with Bipolar I Disorder</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold italics">Adults</content>
                        </paragraph>
                        <paragraph>TheÂ recommendedÂ startingÂ doseÂ of lurasidoneÂ hydrochloride tablets isÂ 20Â mgÂ givenÂ onceÂ dailyÂ asÂ monotherapyÂ orÂ as adjunctiveÂ therapyÂ withÂ lithium orÂ valproate.Â InitialÂ doseÂ titration isÂ notÂ required.Â LurasidoneÂ hydrochloride have beenÂ shownÂ toÂ beÂ effectiveÂ inÂ aÂ doseÂ rangeÂ of 20Â mgÂ perÂ dayÂ toÂ 120Â mgÂ perÂ dayÂ asÂ monotherapy orÂ asÂ adjunctiveÂ therapy withÂ lithiumÂ orÂ valproateÂ <content styleCode="italics">[seeÂ ClinicalÂ StudiesÂ (</content>
                           <linkHtml href="#_d711956a-c8d2-2fb5-6914-2fc9cce2952e">14.2</linkHtml>
                           <content styleCode="italics">)]</content>.Â TheÂ maximum recommendedÂ dose,Â  asÂ monotherapyÂ orÂ asÂ adjunctiveÂ therapyÂ withÂ lithium orÂ valproate,Â isÂ 120 mgÂ perÂ day.Â InÂ theÂ monotherapyÂ study,Â theÂ higher doseÂ rangeÂ (80Â mgÂ toÂ 120Â mgÂ perÂ day)Â didÂ not provideÂ additionalÂ efficacy,Â onÂ average,Â compared toÂ theÂ lowerÂ doseÂ rangeÂ (20Â toÂ 60Â mgÂ perÂ day) <content styleCode="italics">[see Clinical Studies (</content>
                           <linkHtml href="#_d711956a-c8d2-2fb5-6914-2fc9cce2952e">14.2</linkHtml>
                           <content styleCode="italics">)]</content>. Â  </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>The recommended starting dose of lurasidoneÂ hydrochlorideÂ tablets is 20 mg given once daily as monotherapy. Initial dose titration is not required. The dose may be increased after one week based on clinical response. LurasidoneÂ hydrochloride has been shown to be effective in a dose range of 20 mg per day to 80 mg per day as monotherapy. At the end of the clinical study, most of the patients (67%) received 20 mg or 40 mg once daily <content styleCode="italics">[see Clinical Studies (</content>
                           <linkHtml href="#_d711956a-c8d2-2fb5-6914-2fc9cce2952e">14.2</linkHtml>
                           <content styleCode="italics">)]</content>. The maximum recommended dose is 80 mg per day.</paragraph>
                        <paragraph> The efficacy of lurasidone hydrochloride tablets in the treatment of mania associated with bipolar disorder has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_b30d332c-3939-8af6-1706-567e2831f491">
                     <id root="dae5e9ee-49f8-d7a1-1c95-223987b6a042"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.3 Administration Information</title>
                     <text>
                        <paragraph>Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone hydrochloride. Administration with food increases the AUC approximately 2-fold and increases the C<sub>max</sub>Â approximately 3-fold. In the clinical studies, lurasidone hydrochloride was administered with food <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>
                           <content styleCode="italics">)].</content> Â  </paragraph>
                        <paragraph> The effectiveness of lurasidone hydrochloride tablets for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use lurasidone hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient<content styleCode="italics"> [see Dosage and Administration </content>
                           <content> (<linkHtml href="#_fdd5ef0e-2ec4-12e4-3c30-8583c4ee8ae9">2.2</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_83721e04-563e-b6d4-eb60-19c19c0bf51f">
                     <id root="b6db1a15-efed-132e-5f92-160cd68af07c"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.4 Dose Modifications for Renal Impairment</title>
                     <text>
                        <paragraph> Dose adjustment is recommended in moderate (creatinine clearance: 30 to &lt;50 mL/min) and severe renal impairmentÂ (creatinine clearance &lt;30 mL/min) patients. The recommended starting doseÂ isÂ 20Â mgÂ perÂ day.Â TheÂ doseÂ in theseÂ patientsÂ shouldÂ notÂ exceedÂ 80Â mgÂ perÂ day <content styleCode="italics">[seeÂ UseÂ in Specific Populations (</content>
                           <linkHtml href="#_835b2b82-75f8-8a61-729c-d8c451263468">8.6</linkHtml>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_7816ac27-85cb-5181-8780-5bd594b8b4f1">
                     <id root="f47b29cb-80d1-557c-5d38-41fff4436678"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.5 Dose Modifications for Hepatic Impairment</title>
                     <text>
                        <paragraph> Dose adjustment is recommended in moderate (Child-Pugh Score = 7 to 9)Â and severe hepatic impairment (Child-Pugh Score = 10 to 15) patients. The recommended starting dose is 20 mg per day.Â TheÂ doseÂ inÂ moderateÂ hepaticÂ impairmentÂ patientsÂ shouldÂ notÂ exceed 80 mgÂ perÂ dayÂ andÂ the doseÂ inÂ severeÂ hepaticÂ impairmentÂ patients shouldÂ notÂ exceed 40<content> per</content>Â mg/dayÂ <content styleCode="italics">[seeÂ UseÂ inÂ Specific PopulationsÂ (</content>
                           <linkHtml href="#_835b2b82-75f8-8a61-729c-d8c451263468">8.7</linkHtml>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_ae8945bb-e754-49f7-9b4b-31389ad53614">
                     <id root="bea1a926-a941-c16f-d566-da83e3d7dee6"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content>2.6 Dose Modifications Due to Drug Interactions </content>
                        <content>of CYP3A4 Inhibitors and CYP3A4 Inducers</content>
                        <content styleCode="bold"/>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics underline">Concomitant Use with CYP3A4 Inhibitors</content>
                        </paragraph>
                        <paragraph> LurasidoneÂ hydrochloride tablets shouldÂ notÂ beÂ usedÂ concomitantly withÂ aÂ strongÂ CYP3A4Â inhibitor (e.g.,Â ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.)<content styleCode="italics">Â [see Contraindications (</content>
                           <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>
                           <content styleCode="italics">)</content>]. Â </paragraph>
                        <paragraph> If lurasidone hydrochloride tablets are being prescribed and a moderate CYP3A4 inhibitor (e.g. diltiazem, atazanavir, erythromycin, fluconazole, verapamil etc.) is added to the therapy, the lurasidoneÂ hydrochloride tablets dose should be reducedÂ toÂ halfÂ ofÂ theÂ originalÂ doseÂ level. Similarly,Â ifÂ aÂ moderateÂ CYP3A4 inhibitorÂ isÂ being prescribed and lurasidone hydrochloride tablets are added to the therapy, the recommended starting dose of lurasidone hydrochloride tablet is 20Â mgÂ perÂ day,Â andÂ theÂ maximumÂ recommendedÂ doseÂ of lurasidoneÂ hydrochloride tablet isÂ 80Â mgÂ perÂ dayÂ <content styleCode="italics">[see Contraindications (</content>
                           <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>
                           <content styleCode="italics">),Â Drug Interactions (</content>
                           <linkHtml href="#_9033c447-94f5-8fa9-0509-3fa796995fe1">7.1</linkHtml>
                           <content styleCode="italics">)]. </content> Â  </paragraph>
                        <paragraph>GrapefruitÂ andÂ grapefruitÂ juiceÂ shouldÂ beÂ avoidedÂ inÂ patients takingÂ lurasidone hydrochloride tablets,Â sinceÂ theseÂ may inhibit CYP3A4 and alter lurasidone hydrochloride concentrations <content styleCode="italics">[see Drug Interactions (</content>
                           <linkHtml href="#_9033c447-94f5-8fa9-0509-3fa796995fe1">7.1</linkHtml>
                           <content styleCode="italics">)]. Â  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Concomitant Use with CYP3A4 Inducers</content>
                        </paragraph>
                        <paragraph>Lurasidone hydrochloride tablets should not be used concomitantly with a strong CYP3A4 inducer (e.g., rifampin, avasimibe, St. Johnâs wort, phenytoin, carbamazepine, etc.) <content styleCode="italics">[seeÂ ContraindicationsÂ (</content>
                           <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>
                           <content styleCode="italics">);Â Drug Interactions (</content>
                           <linkHtml href="#_9033c447-94f5-8fa9-0509-3fa796995fe1">7.1</linkHtml>
                           <content styleCode="italics">)].</content>Â IfÂ lurasidoneÂ hydrochloride tablets areÂ usedÂ concomitantlyÂ withÂ aÂ moderate CYP3A4Â inducer,Â itÂ may be necessary to increase the lurasidone hydrochloride tablets dose after chronic treatment (7 days or more) with the CYP3A4 inducer.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DOSAGE_FORMS_AND_STRENGTHS">
               <id root="0d7dfc74-c2ed-55b8-6001-2cc309c9a428"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Lurasidone hydrochloride tabletsÂ areÂ availableÂ inÂ theÂ followingÂ shapeÂ andÂ color (Table 1)Â withÂ respective two-sidedÂ debossing.Â  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 1: Lurasidone Hydrochloride Tablet Presentations</content>
                     <content styleCode="bold">Â </content>
                  </paragraph>
                  <table>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Tablet Strength </content>
                           </td>
                           <td>
                              <content styleCode="bold">Tablet Color/Shape</content>
                           </td>
                           <td>
                              <content styleCode="bold">Tablet Markings</content>
                              <content styleCode="bold">Â </content>
                           </td>
                        </tr>
                        <tr>
                           <td>20 mg </td>
                           <td>white to off-white round </td>
                           <td>351;20<content styleCode="bold">Â </content>
                           </td>
                        </tr>
                        <tr>
                           <td>40 mg </td>
                           <td>white to off-white round </td>
                           <td>352;40<content styleCode="bold">Â </content>
                           </td>
                        </tr>
                        <tr>
                           <td>60 mg </td>
                           <td>white to off-white capsule shape </td>
                           <td>353;60<content styleCode="bold">Â </content>
                           </td>
                        </tr>
                        <tr>
                           <td>80 mg </td>
                           <td>
                              <content>pale</content> green oval </td>
                           <td>354;80<content styleCode="bold">Â </content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets:Â 20Â mg,Â 40Â mg,Â 60 mg andÂ 80Â mgÂ (<linkHtml href="#DOSAGE_FORMS_AND_STRENGTHS">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="CONTRAINDICATIONS">
               <id root="d9c977a9-85cb-0171-ec49-efd2b488ce3a"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>â¢ Known Â hypersensitivity Â to Â lurasidone Â HCl Â or Â any Â components Â in Â the Â formulation. AngioedemaÂ has been observed with lurasidoneÂ <content styleCode="italics">[see Adverse Reactions (</content>
                     <linkHtml href="#_9498837b-165d-9d5c-29fb-665e4deaba58">6.1</linkHtml>
                     <content styleCode="italics">)]</content>. </paragraph>
                  <paragraph>â¢ StrongÂ CYP3A4Â inhibitorsÂ (e.g.,Â ketoconazole,Â clarithromycin,Â ritonavir,Â voriconazole, mibefradil, etc.) <content styleCode="italics">[see Drug Interactions (</content>
                     <linkHtml href="#_9033c447-94f5-8fa9-0509-3fa796995fe1">7.1</linkHtml>
                     <content styleCode="italics">)]. </content>
                  </paragraph>
                  <paragraph> â¢ Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. Â Johnâs wort, phenytoin, carbamazepine, etc.) <content styleCode="italics">[see Drug Interactions (</content>
                     <linkHtml href="#_9033c447-94f5-8fa9-0509-3fa796995fe1">7.1</linkHtml>
                     <content styleCode="italics">)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>KnownÂ hypersensitivityÂ toÂ lurasidone hydrochlorideÂ orÂ anyÂ componentsÂ inÂ the formulationÂ (<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>).</item>
                           <item>ConcomitantÂ useÂ withÂ aÂ strongÂ CYP3A4Â inhibitorÂ (e.g., ketoconazole)Â (<linkHtml href="#_7816ac27-85cb-5181-8780-5bd594b8b4f1">2.6</linkHtml>,Â <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>,Â <linkHtml href="#_9033c447-94f5-8fa9-0509-3fa796995fe1">7.1</linkHtml>).</item>
                           <item>ConcomitantÂ useÂ withÂ aÂ strongÂ CYP3A4Â inducerÂ (e.g.,Â rifampin) (<linkHtml href="#_7816ac27-85cb-5181-8780-5bd594b8b4f1">2.6</linkHtml>,Â <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>,Â <linkHtml href="#_9033c447-94f5-8fa9-0509-3fa796995fe1">7.1</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="WARNINGS_AND_PRECAUTIONS">
               <id root="25f24f6e-def1-ff15-64eb-d0ac281a8363"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>
                              <content styleCode="underline">CerebrovascularÂ AdverseÂ ReactionsÂ inÂ ElderlyÂ PatientsÂ with Dementia-RelatedÂ Psychosis</content>:Â IncreasedÂ incidenceÂ of cerebrovascularÂ adverseÂ eventsÂ (e.g.,Â stroke,Â transientÂ ischemic attack)Â (<linkHtml href="#_f7865b38-4a30-8823-3ad1-c93d6790b2a7">5.3</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">NeurolepticÂ MalignantÂ Syndrome</content>:Â ManageÂ withÂ immediate discontinuationÂ andÂ close monitoringÂ (<linkHtml href="#_2597bb6f-80c9-5f91-5c55-9068d1acbf85">5.4</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">TardiveÂ Dyskinesia</content>:Â DiscontinueÂ ifÂ clinicallyÂ appropriateÂ (<linkHtml href="#_cf40cc08-2a0c-7eca-6b2f-5883e42f251e">5.5</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">MetabolicÂ Changes</content>:Â Monitor for hyperglycemia/diabetes mellitus,Â dyslipidemiaÂ andÂ weightÂ gainÂ (<linkHtml href="#_728ef4cc-2114-48f5-157f-2cd238c2da9e">5.6</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">Hyperprolactinemia</content>:Â ProlactinÂ elevationsÂ mayÂ occurÂ (<linkHtml href="#_bc1f52e9-67f4-8271-ff7e-e7cc04d8ec54">5.7</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">Leukopenia,Â Neutropenia,Â andÂ Agranulocytosis</content>:Â PerformÂ complete bloodÂ countsÂ (CBC)Â inÂ patientsÂ withÂ aÂ pre-existingÂ lowÂ whiteÂ blood cellÂ countÂ (WBC)Â orÂ aÂ historyÂ ofÂ leukopeniaÂ orÂ neutropenia. ConsiderÂ discontinuingÂ lurasidone hydrochlorideÂ tablets ifÂ aÂ clinicallyÂ significantÂ decline inÂ WBCÂ occursÂ in theÂ absenceÂ ofÂ otherÂ causativeÂ factorsÂ (<linkHtml href="#_3bcfe14b-6741-4ff0-3487-cf641edd449a">5.8</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">OrthostaticÂ HypotensionÂ andÂ Syncope</content>:Â Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncopeÂ (<linkHtml href="#_e2e5a0af-303a-3a0d-9210-0cfc2550de00">5.9</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_9a2c7fa4-f522-abb9-14e6-f251720c410d">
                     <id root="307872b5-f7da-b4c2-e4d4-f885ff89cbea"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.1 IncreasedÂ MortalityÂ inÂ ElderlyÂ PatientsÂ withÂ Dementia-Related Psychosis</title>
                     <text>
                        <paragraph>Elderly Â patients Â with Â dementia-related Â psychosis Â treated Â with Â antipsychotic Â drugs Â are Â at Â an increasedÂ riskÂ ofÂ death. AnalysesÂ ofÂ 17Â placebo-controlledÂ trialsÂ (modalÂ duration ofÂ 10Â weeks), largelyÂ inÂ patientsÂ takingÂ atypicalÂ antipsychoticÂ drugs,Â revealedÂ aÂ riskÂ ofÂ deathÂ inÂ drug-treated patients of between 1.6- to 1.7-times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, comparedÂ toÂ aÂ rateÂ ofÂ aboutÂ 2.6%Â inÂ theÂ placebo group.Â AlthoughÂ theÂ causesÂ ofÂ deathÂ were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Lurasidone hydrochloride tabletsÂ areÂ notÂ approved forÂ theÂ treatmentÂ ofÂ patientsÂ withÂ dementia-relatedÂ psychosis <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#BOXED_WARNING"> Boxed Warning</linkHtml>
                           </content>, <content styleCode="italics">Warnings and Precautions</content> (<linkHtml href="#_f7865b38-4a30-8823-3ad1-c93d6790b2a7">5.3</linkHtml>)<content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_f4c6c181-4e79-9e4b-fac8-30b76b163a6c">
                     <id root="8773b812-f076-f1f3-41a7-37abeda2cd55"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content/>5.2 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients</title>
                     <text>
                        <paragraph>In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients, and over 4,400 pediatric patients, the incidence of suicidal thoughts and behaviors in pediatric and young adult patients was greater in antidepressant-treated patients than in placebo-treated patients. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 2. Â  </paragraph>
                        <paragraph> No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on suicide.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2: Risk Differences of the Number of Cases of Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold"> Age Range</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Drug-Placebo Difference in Number of Patients of Suicidal Thoughts or Behaviors per 1,000 Patients Treated</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> Â  </td>
                                 <td> Increases Compared to Placebo </td>
                              </tr>
                              <tr>
                                 <td> &lt;18 </td>
                                 <td> 14 additional patients </td>
                              </tr>
                              <tr>
                                 <td> 18 to 24 </td>
                                 <td> 5 additionalÂ patients </td>
                              </tr>
                              <tr>
                                 <td> Â  </td>
                                 <td> Decreases Compared to Placebo </td>
                              </tr>
                              <tr>
                                 <td> 25 to 64 </td>
                                 <td> 1 fewer patient</td>
                              </tr>
                              <tr>
                                 <td> â¥65 </td>
                                 <td> 6 fewer patients </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> It is unknown whether the risk of suicidal thoughts and behaviors in pediatric and young adult patients extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. Â  Â  Â  </paragraph>
                        <paragraph>Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing lurasidone hydrochloride tablets, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_f7865b38-4a30-8823-3ad1-c93d6790b2a7">
                     <id root="d1afa092-dcc2-fd6b-cc9b-575291030242"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3  Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis</title>
                     <text>
                        <paragraph>InÂ placebo-controlledÂ trialsÂ withÂ risperidone,Â aripiprazole,Â andÂ olanzapineÂ inÂ elderlyÂ subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidentsÂ andÂ transientÂ ischemicÂ attacks), includingÂ fatalities,Â comparedÂ to placebo-treated subjects. Lurasidone hydrochloride tablets are not approved for the treatment of patients with dementia-related psychosis <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#BOXED_WARNING">Boxed Warning</linkHtml>
                           </content>
                           <content styleCode="italics">, Warnings and Precautions</content>
                           <content styleCode="bold">
                              <linkHtml href="#_9a2c7fa4-f522-abb9-14e6-f251720c410d">(5.1</linkHtml>
                           </content>)<content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_2597bb6f-80c9-5f91-5c55-9068d1acbf85">
                     <id root="37c3376e-d286-0d1b-55f3-6007478e4ffa"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.4  Neuroleptic Malignant Syndrome</title>
                     <text>
                        <paragraph>AÂ potentiallyÂ fatalÂ symptom complexÂ sometimesÂ referredÂ toÂ asÂ NeurolepticÂ MalignantÂ Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including lurasidone hydrochloride. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidenceÂ ofÂ autonomicÂ instability. <content>AdditionalÂ signs mayÂ includeÂ elevatedÂ creatineÂ phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.</content>
                        </paragraph>
                        <paragraph>If NMS is suspected, immediately discontinue lurasidone hydrochloride tablets and provide intensive symptomatic treatment and monitoring.Â </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_cf40cc08-2a0c-7eca-6b2f-5883e42f251e">
                     <id root="729ece80-1149-6185-01dd-a3293cb789c2"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.5 Tardive Dyskinesia</title>
                     <text>
                        <paragraph>Tardive dyskinesia is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements Â that can Â develop Â in Â patients Â treated Â with Â antipsychotic Â drugs. Â Although Â the prevalence of the syndromeÂ appears to be highest among the elderly, especially elderly women, it isÂ impossibleÂ toÂ relyÂ uponÂ prevalenceÂ estimatesÂ to predict,Â atÂ theÂ inceptionÂ ofÂ antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential toÂ cause tardive dyskinesia is unknown.Â </paragraph>
                        <paragraph>
                           <content>TheÂ riskÂ ofÂ developingÂ tardiveÂ dyskinesiaÂ andÂ theÂ likelihood thatÂ itÂ willÂ becomeÂ irreversibleÂ are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However,</content> the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment.Â Â Â </paragraph>
                        <paragraph>The syndrome mayÂ remit,Â partiallyÂ orÂ completely,Â ifÂ antipsychotic treatmentÂ isÂ withdrawn.Â Antipsychotic treatment,Â itself,Â however,Â mayÂ suppressÂ (orÂ partiallyÂ suppress)Â theÂ signsÂ andÂ symptomsÂ ofÂ the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-termÂ course of the syndrome is unknown.Â </paragraph>
                        <paragraph>Given these considerations, lurasidone hydrochloride tabletsÂ should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally beÂ reservedÂ forÂ patientsÂ whoÂ sufferÂ from aÂ chronicÂ illnessÂ thatÂ (1)Â isÂ knownÂ toÂ respondÂ to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatmentsÂ areÂ notÂ availableÂ orÂ appropriate.Â In patientsÂ whoÂ doÂ requireÂ chronicÂ treatment,Â the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.Â </paragraph>
                        <paragraph>If signs and symptoms of tardive dyskinesia appear in a patient on lurasidone hydrochloride tablets, drug discontinuation should be considered. However, some patients may require treatment with lurasidone hydrochloride tablets despite the presence of the syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_728ef4cc-2114-48f5-157f-2cd238c2da9e">
                     <id root="8768132a-e2c9-c520-4c19-b3c57d4d3a80"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.6  Metabolic Changes</title>
                     <text>
                        <paragraph>Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drugÂ has its own specific risk profile.</paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Hyperglycemia and Diabetes Mellitus</content>
                        </paragraph>
                        <paragraph>Hyperglycemia,Â inÂ someÂ casesÂ extremeÂ andÂ associatedÂ withÂ ketoacidosisÂ orÂ hyperosmolarÂ coma orÂ death,Â hasÂ beenÂ reported inÂ patientsÂ treated withÂ atypicalÂ antipsychotics.Â Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increasedÂ riskÂ ofÂ Â hyperglycemia-relatedÂ adverseÂ events inÂ patientsÂ treated withÂ theÂ atypicalÂ antipsychotics.Â </paragraph>
                        <paragraph>Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factorsÂ forÂ diabetesÂ mellitus (e.g.,Â obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptomsÂ of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolvedÂ whenÂ theÂ atypicalÂ antipsychoticÂ was discontinued;Â however,Â someÂ patientsÂ required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar Depression </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>Data Â from Â the Â adult short-term, Â flexible-dose, Â placebo-controlled Â monotherapy Â bipolar Â depression study are presented in Table 4.Â  </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 4: Change in Fasting Glucose in the Adult Monotherapy Bipolar Depression Study</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td/>
                                 <td/>
                                 <td align="center" colspan="2">
                                    <content styleCode="bold">Lurasidone Hydrochloride</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">20 to 60 mg/day </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">80 to 120 mg/day</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="4">
                                    <content styleCode="bold">Mean Change from Baseline (mg/dL)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">n=148</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">n=140</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">n=143</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Serum Glucose </td>
                                 <td>+1.8</td>
                                 <td>-0.8</td>
                                 <td>+1.8</td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="4">
                                    <content styleCode="bold">Proportion of Patients with Shifts to â¥126 mg/dL</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Serum Glucose (â¥ 126 mg/dL) </td>
                                 <td>4.3% (6/141) </td>
                                 <td>2.2% (3/138) </td>
                                 <td>6.4%(9/141)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Patients wereÂ randomized to flexiblyÂ dosedÂ lurasidoneÂ hydrochloride 20 to 60 mg/day, lurasidone hydrochlorideÂ 80 toÂ 120 mg/day,Â or placeboÂ </paragraph>
                        <paragraph>InÂ theÂ uncontrolled,Â open-label,Â longer-term bipolarÂ depressionÂ study,Â patientsÂ whoÂ received lurasidoneÂ hydrochloride as monotherapy inÂ theÂ short-term studyÂ andÂ continuedÂ inÂ theÂ longer-term study,Â hadÂ a mean change in glucose of +1.2 mg/dL at week 24 (n=129).Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or Valproate</content>
                        </paragraph>
                        <paragraph>DataÂ fromÂ theÂ adult short-term,Â flexible-dosed, placebo-controlledÂ adjunctiveÂ therapyÂ bipolar depression studies are presented inÂ Table 5.</paragraph>
                        <paragraph>
                           <content styleCode="bold"> Table 5: Change in Fasting Glucose in the Adult Adjunctive Therapy Bipolar Depression S</content>
                           <content styleCode="bold">tudies</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Lurasidone Hydrochloride </content>
                                    <content styleCode="bold">
                                       <br/>20Â toÂ 120Â mg/day</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="3">
                                    <content styleCode="bold">MeanÂ ChangeÂ fromÂ BaselineÂ (mg/dL)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td align="center">
                                    <content styleCode="bold">n=302</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">n=319</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>SerumÂ Glucose</td>
                                 <td align="center">-0.9</td>
                                 <td align="center">+1.2</td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="3">
                                    <content styleCode="bold">ProportionÂ ofÂ PatientsÂ withÂ ShiftsÂ toÂ </content>â¥Â <content styleCode="bold">126Â mg/dL</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>SerumÂ Glucose</td>
                                 <td align="center">1.0%</td>
                                 <td align="center">1.3%</td>
                              </tr>
                              <tr>
                                 <td>(â¥Â 126 mg/dL)</td>
                                 <td align="center">(3/290)</td>
                                 <td align="center">(4/316)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Patients wereÂ randomized to flexiblyÂ dosedÂ lurasidone hydrochloride 20 to 120 mg/dayÂ or placebo as adjunctive therapy with lithiumÂ or valproate.Â </paragraph>
                        <paragraph>InÂ theÂ uncontrolled,Â open-label,Â longer-term bipolarÂ depressionÂ study,Â patientsÂ whoÂ received lurasidoneÂ hydrochloride asÂ adjunctiveÂ therapyÂ withÂ eitherÂ lithiumÂ orÂ valproateÂ inÂ theÂ short-term studyÂ and continuedÂ inÂ theÂ longer-termÂ study,Â hadÂ aÂ meanÂ changeÂ inÂ glucoseÂ ofÂ +1.7Â mg/dLÂ atÂ weekÂ 24 (n=88). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>In studies of pediatric patients 10 to 17 years and adults with bipolar depression, changes in fasting glucose were similar. In the 6-week, placebo-controlled study of pediatric patients with bipolar depression, mean change in fasting glucose was +1.6 mg/dL for lurasidone hydrochloride 20 to 80 mg/day (n=145) and -0.5 mg/dL for placebo (n=145).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (6 to 17 years) </content>
                        </paragraph>
                        <paragraph>In a 104-week, open-label study in pediatric patients with bipolar depression, autistic disorder or another disorder, 7 % of patients with a normal baselin e fasting glucose experienced a shift to high at endpoint while taking lurasidone.</paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Dyslipidemia</content>
                        </paragraph>
                        <paragraph>Undesirable Â alterations Â in Â lipids Â have Â been Â observed Â in Â patients Â treated Â with Â atypical antipsychotics.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar Depression </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                           <content styleCode="italics underline"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>DataÂ fromÂ theÂ adult short-term,Â flexible-dosed,Â placebo-controlled,Â monotherapyÂ bipolarÂ depression study are presented in Table 7.Â  </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 7: Change in Fasting Lipids in the Adult Monotherapy Bipolar Depression Study</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td align="center" colspan="2">
                                    <content styleCode="bold">Lurasidone Hydrochloride</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">20 to 60 mg/day</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">80 to </content>
                                    <content styleCode="bold">120 mg/day</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="4">
                                    <content styleCode="bold">Mean Change from Baseline (mg/dL)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">n=147</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">n=140</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">n=144</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Total cholesterol </td>
                                 <td>-3.2</td>
                                 <td>+1.2</td>
                                 <td>-4.6</td>
                              </tr>
                              <tr>
                                 <td>Triglycerides </td>
                                 <td>+6.0</td>
                                 <td>+5.6</td>
                                 <td>+0.4</td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="4">
                                    <content styleCode="bold">Proportion of Patients with Shifts</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Total cholesterol (â¥ 240 mg/dL) </td>
                                 <td>4.2% (5/118)</td>
                                 <td>4.4% (5/113)</td>
                                 <td>4.4% (5/114)</td>
                              </tr>
                              <tr>
                                 <td>Triglycerides (â¥ 200 mg/dL) </td>
                                 <td>4.8% (6/126)</td>
                                 <td>10.1% (12/119)</td>
                                 <td>9.8% (12/122)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content>Patients wereÂ randomized to flexiblyÂ dosedÂ lurasidoneÂ hydrochloride 20 to 60 mg/day, lurasidone hydrochloride 80 toÂ 120 mg/day,Â or placeboÂ </content>
                        </paragraph>
                        <paragraph>
                           <content>InÂ theÂ uncontrolled,Â open-label,Â longer-term bipolarÂ depressionÂ study,Â patientsÂ whoÂ received lurasidoneÂ hydrochloride asÂ monotherapyÂ inÂ theÂ short-term andÂ continuedÂ inÂ theÂ longer-term studyÂ hadÂ aÂ mean changeÂ inÂ totalÂ cholesterolÂ and triglyceridesÂ ofÂ -0.5Â mg/dL (n=130)Â andÂ -1mg/dLÂ (n=130)Â  atÂ weekÂ 24, respectively.Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or Valproate</content>
                           <content>Â </content>
                        </paragraph>
                        <paragraph>
                           <content>DataÂ fromÂ theÂ adult short-term,Â flexible-dosed, placebo-controlled,Â adjunctiveÂ therapyÂ bipolar depression studies are presented inÂ Table 8.Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 8: Change in Fasting Lipids in the Adult Adjunctive Therapy Bipolar Depression Studies</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td/>
                                 <td align="center">
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Lurasidone Hydrochloride</content>
                                    <content styleCode="bold">
                                       <br/>20 to 120 mg/day</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td align="center" colspan="2">
                                    <content styleCode="bold">Mean Change from Baseline (mg/dL)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td align="center">
                                    <content styleCode="bold">n=303</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">n=321</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Total cholesterol</td>
                                 <td align="center">-2.9</td>
                                 <td align="center">-3.1</td>
                              </tr>
                              <tr>
                                 <td>Triglycerides</td>
                                 <td align="center">-4.6</td>
                                 <td align="center">+4.6</td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td align="center" colspan="2">
                                    <content styleCode="bold">Proportion of Patients with Shifts</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Total cholesterol(â¥ 240 mg/dL)</td>
                                 <td align="center">5.7%(15/263)</td>
                                 <td align="center">5.4%(15/276)</td>
                              </tr>
                              <tr>
                                 <td>Triglycerides(â¥ 200 mg/dL)</td>
                                 <td align="center">8.6%(21/243)</td>
                                 <td align="center">10.8%(28/260)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> Patients wereÂ randomized to flexiblyÂ dosedÂ lurasidone hydrochloride 20 to 120 mg/dayÂ or placebo as adjunctive therapy with lithiumÂ or valproate.Â </paragraph>
                        <paragraph>InÂ theÂ uncontrolled,Â open-label,Â longer-term bipolarÂ depressionÂ study,Â patientsÂ whoÂ received lurasidone hydrochloride, as adjunctive therapy withÂ eitherÂ lithium orÂ valproateÂ inÂ theÂ short-term studyÂ and continuedÂ inÂ theÂ longer-term study, had a mean change in total cholesterolÂ andÂ triglyceridesÂ of -0.9 (n=88) and +5.3 (n=88) mg/dL at week 24, respectively.Â </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>In the 6-week, placebo-controlled bipolar depression study with pediatric patients 10 to 17 years, mean change in fasting cholesterol was -6.3 mg/dL for lurasidone hydrochloride 20 to 80 mg/day (n=144) and -1.4 mg/dL for placebo (n=145), and mean change in fasting triglyceride was â7.6 mg/dL for lurasidone hydrochloride 20 to 80 mg/day (n=144) and +5.9 mg/dL for placebo (n=145).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (6 to 17 years)</content>
                        </paragraph>
                        <paragraph>In a 104-week, open-label study in pediatric patients with bipolar depression, autistic disorder or another disorder, shifts in baseline fasting cholesterol from normal to high at endpoint were reported in 12% (total cholesterol), 3% (LDL cholesterol), and shifts in baseline from normal to low were reported in 27% (HDL cholesterol) of patients taking lurasidone. Of patients with normal baseline fasting triglycerides, 12% experienced shifts to high.</paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Weight Gain</content>
                        </paragraph>
                        <paragraph>WeightÂ gainÂ hasÂ beenÂ observedÂ withÂ atypicalÂ antipsychoticÂ use.Â Clinical monitoring ofÂ weightÂ is recommended.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar Depression </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>DataÂ from theÂ adult short-term,Â flexible-dosed,Â placebo-controlledÂ monotherapyÂ bipolarÂ depression studyÂ areÂ presentedÂ inÂ Table 11.Â TheÂ mean change inÂ weightÂ gainÂ wasÂ +0.29Â kgÂ forÂ lurasidone hydrochloride-treated patientsÂ comparedÂ toÂ -0.04Â kgÂ forÂ placebo-treatedÂ patients.Â TheÂ proportionÂ ofÂ patientsÂ withÂ a Â â¥7% increase in body weight (at Endpoint) was 2.4% for lurasidone hydrochloride-treated patients and 0.7% for placebo-treated patients. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 11: Mean Change in Weight (kg) from Baseline in the Adult Monotherapy Bipolar Depression Study</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td align="center" colspan="2">
                                    <content styleCode="bold">Lurasidone Hydrochloride</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">20Â toÂ 60Â mg/day</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">80Â toÂ 120Â mg/day</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td align="center">
                                    <content styleCode="bold">(n=151)</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">(n=143)</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">(n=147)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>AllÂ Patients</td>
                                 <td align="center">-0.04</td>
                                 <td align="center">+0.56</td>
                                 <td align="center">+0.02</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> Patients wereÂ randomized to flexiblyÂ dosedÂ lurasidoneÂ hydrochloride 20 to 60 mg/day, lurasidone hydrochloride 80 toÂ 120 mg/day,Â or placeboÂ </paragraph>
                        <paragraph>InÂ theÂ uncontrolled,Â open-label,Â longer-term bipolarÂ depressionÂ study,Â patientsÂ whoÂ received lurasidoneÂ hydrochloride asÂ monotherapyÂ inÂ theÂ short-term andÂ continuedÂ inÂ theÂ longer-term studyÂ hadÂ aÂ mean change in weight of -0.02 kg at week 24 (n=130).Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or ValproateÂ </content>
                        </paragraph>
                        <paragraph>DataÂ fromÂ theÂ adult short-term,Â flexible-dosed, placebo-controlledÂ adjunctiveÂ therapyÂ bipolar depressionÂ studiesÂ areÂ presentedÂ inÂ Table 12.Â TheÂ mean change inÂ weightÂ gainÂ wasÂ +0.11Â kgÂ forÂ lurasidone hydrochloride- treatedÂ patientsÂ comparedÂ toÂ +0.16Â kgÂ forÂ placebo-treatedÂ patients.Â TheÂ proportionÂ ofÂ patients withÂ aÂ â¥7%Â increaseÂ inÂ bodyÂ weightÂ (atÂ Endpoint)Â wasÂ 3.1%Â forÂ lurasidone hydrochloride-treatedÂ patients and 0.3% for placebo-treated patients. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 12: Mean Change in Weight (kg) from Baseline in the Adult Adjunctive Therapy Bipolar Depression Studies</content>
                        </paragraph>
                        <table frame="border" rules="all">
                           <tbody>
                              <tr>
                                 <td/>
                                 <td align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>(n=307)</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Lurasidone Hydrochloride</content>
                                    <content styleCode="bold">
                                       <br/>20Â toÂ 120Â mg/day<br/>
                                    </content>
                                    <content styleCode="bold">(n=327)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>AllÂ Patients</td>
                                 <td align="center">+0.16</td>
                                 <td align="center">+0.11</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> Patients wereÂ randomized to flexiblyÂ dosedÂ lurasidone hydrochloride 20 to 120 mg/dayÂ or placebo as adjunctive therapy with lithiumÂ or valproate.</paragraph>
                        <paragraph>InÂ theÂ uncontrolled,Â open-label,Â longer-term bipolarÂ depressionÂ study,Â patientsÂ whoÂ wereÂ treated withÂ lurasidone hydrochloride,Â asÂ adjunctiveÂ therapyÂ withÂ eitherÂ lithium orÂ valproateÂ inÂ theÂ short-term and continued in the longer-termÂ study, had a mean change in weight of +1.28 kg at week 24 (n=86).Â </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>Data from the 6-week, placebo-controlled bipolar depression study in patients 10 to 17 years are presented in Table 13. The mean change in weight gain was +0.7 kg for lurasidone hydrochloride-treated patients compared to +0.5 kg for placebo-treated patients. The proportion of patients with a â¥7% increase in body weight (at Endpoint) was 4% for lurasidone hydrochloride-treated patients and 5.3% for placebo-treated patients. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 13: Mean Change in Weight (kg) from Baseline in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td/>
                                 <td align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>(n=170)</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Lurasidone Hydrochloride</content>
                                    <content styleCode="bold">
                                       <br/>20 to 80 mg/day</content>
                                    <content styleCode="bold">
                                       <br/>(n=175)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>All Patients</td>
                                 <td align="center">+0.5</td>
                                 <td align="center">+0.7</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (6 to 17 years)</content>
                        </paragraph>
                        <paragraph>In a long-term, open-label study that enrolled pediatric patients with bipolar depression, autistic disorder or another disorder from three short-term, placebo-controlled trials, 54% (378/701) received lurasidone for 104 weeks. The mean increase in weight from open-label baseline to Week 104 was 5.85 kg. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of children and adolescents by comparisons to age- and sex-matched population standards. A z-score change &lt;0.5 SD is considered not clinically significant. In this trial, the mean change in z-score from open-label baseline to Week 104 was -0.06 SD for body weight and -0.13 SD for body mass index (BMI), indicating minimal deviation from the normal curve for weight gain.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_bc1f52e9-67f4-8271-ff7e-e7cc04d8ec54">
                     <id root="17b5b0da-6ec4-170f-f3ab-41304e19154e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.7  Hyperprolactinemia</title>
                     <text>
                        <paragraph>As with other drugs that antagonize dopamine D<sub>2Â </sub>receptors, lurasidone hydrochloride Â elevates prolactin levels.Â </paragraph>
                        <paragraph>Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds. Long-standing hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone density in both female and male patients<content styleCode="italics"> [see Adverse Reactions</content> (<content styleCode="bold">
                              <linkHtml href="#ADVERSE_REACTIONS">6</linkHtml>
                           </content>)<content styleCode="italics">]</content>.Â </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent inÂ vitro,Â aÂ factorÂ ofÂ potentialÂ importance ifÂ theÂ prescriptionÂ ofÂ theseÂ drugsÂ is consideredÂ inÂ aÂ patientÂ withÂ previously detectedÂ breastÂ cancer.Â AsÂ is commonÂ withÂ compounds whichÂ increaseÂ prolactinÂ release,Â anÂ increase inÂ mammaryÂ glandÂ neoplasiaÂ wasÂ observedÂ inÂ a carcinogenicity study conducted with lurasidone in rats and mice</content>
                           <content styleCode="italics">[seeÂ NonclinicalÂ Toxicology</content>Â (<content styleCode="bold">
                              <linkHtml href="#NONCLINICAL_TOXICOLOGY">13</linkHtml>
                           </content>)<content styleCode="italics">].</content>
                           <content styleCode="xmChange">Published epidemiologic studies have shown inconsistent results when exploring the potential association between hyperprolactinemia and breast cancer</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar Depression </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>TheÂ medianÂ changeÂ from baselineÂ toÂ endpointÂ inÂ prolactin levels,Â inÂ theÂ adultÂ short-term,Â flexible-dosed, placebo-controlled monotherapy bipolar depression study, was +1.7 ng/mL and +3.5 ng/mL with lurasidone hydrochloride 20 to 60 mg/day and 80 to 120 mg/day, respectively compared to +0.3 ng/mLÂ withÂ placebo-treatedÂ patients. TheÂ medianÂ changeÂ fromÂ baseline toÂ endpointÂ forÂ males was +1.5Â ng/mLÂ andÂ forÂ femalesÂ wasÂ +3.1Â ng/mL.Â MedianÂ changesÂ forÂ prolactin byÂ doseÂ range are shown in Table 16.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 16: Median Change in Prolactin (ng/mL) from Baseline in the Adult Monotherapy Bipolar Depression Study</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td colspan="3">
                                    <content styleCode="bold">Lurasidone Hydrochloride</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">20Â toÂ 60Â mg/day</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">80Â toÂ 120Â mg/day</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">AllÂ Patients</td>
                                 <td>+0.3 (n=147)</td>
                                 <td>+1.7 (n=140)</td>
                                 <td colspan="2">+3.5 (n=144)</td>
                              </tr>
                              <tr>
                                 <td align="left">Females</td>
                                 <td>0.0 <br/>(n=82)</td>
                                 <td>+1.8 (n=78)</td>
                                 <td colspan="2">+5.3 (n=88)</td>
                              </tr>
                              <tr>
                                 <td align="left">Males</td>
                                 <td>+0.4 <br/>(n=65)</td>
                                 <td>+1.2 (n=62)</td>
                                 <td colspan="2">+1.9 (n=56)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Patients wereÂ randomized to flexiblyÂ dosedÂ lurasidoneÂ hydrochloride 20 to 60 mg/day, lurasidone hydrochloride 80 toÂ 120 mg/day,Â or placebo</paragraph>
                        <paragraph>The proportion of patients with prolactin elevations â¥5x upper limit of normal (ULN) was 0.4% for lurasidone hydrochloride-treated patients and 0% for placebo-treated patients. The proportion of female patientsÂ withÂ prolactinÂ elevations â¥5xÂ ULNÂ wasÂ 0.6%Â forÂ lurasidone hydrochloride-treatedÂ patientsÂ andÂ 0% forÂ placebo-treated femaleÂ patients.Â TheÂ proportionÂ ofÂ maleÂ patientsÂ withÂ prolactinÂ elevations â¥5x ULN wasÂ 0% and 0% for placebo-treated male patients. </paragraph>
                        <paragraph>InÂ theÂ uncontrolled,Â open-label,Â longer-term bipolarÂ depressionÂ study,Â patientsÂ whoÂ wereÂ treated withÂ lurasidone hydrochloride asÂ monotherapyÂ inÂ theÂ short-termÂ andÂ continuedÂ inÂ theÂ longer-term study,Â hadÂ a median change in prolactin of -1.15 ng/mL at week 24 (n=130).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or Valproate</content>
                        </paragraph>
                        <paragraph>TheÂ medianÂ changeÂ from baselineÂ toÂ endpointÂ inÂ prolactin levels,Â inÂ theÂ adultÂ short-term,Â flexible- dosed, placebo-controlled adjunctive therapy bipolar depression studies was +2.8 ng/mL with lurasidoneÂ hydrochloride 20Â toÂ 120Â mg/dayÂ comparedÂ toÂ 0Â ng/mLÂ withÂ placebo-treated patients.Â TheÂ median change from baseline to endpoint for males was +2.4 ng/mL and for females was +3.2 ng/mL. Median changes for prolactin across the dose range are shown inÂ Table 17.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 17: Median Change in Prolactin (ng/mL) from Baseline in the Adult Adjunctive Therapy Bipolar Depression Studies</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Lurasidone Hydrochloride<br/>
                                    </content>
                                    <content styleCode="bold">20Â toÂ 120Â mg/day</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">AllÂ Patients</td>
                                 <td>0.0 <br/>(n=301)</td>
                                 <td>+2.8 <br/>(n=321)</td>
                              </tr>
                              <tr>
                                 <td align="left">Females</td>
                                 <td>+0.4 <br/>(n=156)</td>
                                 <td>+3.2<br/>(n=162)</td>
                              </tr>
                              <tr>
                                 <td align="left">Males</td>
                                 <td>-0.1 <br/>(n=145)</td>
                                 <td>+2.4<br/>(n=159)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Patients wereÂ randomized to flexiblyÂ dosedÂ lurasidone hydrochloride 20 to 120 mg/dayÂ or placebo as adjunctive therapy with lithiumÂ or valproate. </paragraph>
                        <paragraph>The proportion of patients with prolactin elevations â¥5x upper limit of normal (ULN) was 0% for lurasidone hydrochloride-treated patients and 0% for placebo-treated patients. The proportion of female patients with prolactin elevations â¥5x ULN wasÂ 0% for lurasidone hydrochloride-treated patients and 0% for placebo-treatedÂ femaleÂ patients.Â TheÂ proportionÂ ofÂ maleÂ patientsÂ withÂ prolactinÂ elevationsÂ â¥5x ULN was 0% and 0% for placebo-treated male patients.Â </paragraph>
                        <paragraph>In the uncontrolled, open-label, longer-termÂ bipolar depression study, patients who were treated with lurasidone hydrochloride, as adjunctive therapy with either lithiumÂ or valproate, in the short-termÂ and continued in the longer-termÂ study, had a median change in prolactin of -2.9 ng/mL at week 24 (n=88).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>In the 6-week, placebo-controlled bipolar depression study with pediatric patients 10 to 17 years, the median change from baseline to endpoint in prolactin levels for lurasidone hydrochloride-treated patients was +1.10 ng/mL and was +0.50 ng/mL for placebo-treated patients. For lurasidone hydrochloride-treated patients, the median change from baseline to endpoint for males was +0.85 ng/mL and for females was +2.50 ng/mL. Median changes for prolactin are shown in Table 18. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 18: Median Change in Prolactin (ng/mL) from Baseline in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <thead>
                              <tr>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Lurasidone Hydrochloride </content>
                                    <content styleCode="bold">
                                       <br/>20 to 80 mg/day</content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left">All Patients</td>
                                 <td align="center">+0.50<br/>(n=157)</td>
                                 <td align="center">+1.10<br/>(n=165)</td>
                              </tr>
                              <tr>
                                 <td align="left">Females</td>
                                 <td align="center">+0.55<br/>(n=78)</td>
                                 <td align="center">+2.50<br/>(n=83)</td>
                              </tr>
                              <tr>
                                 <td align="left">Males</td>
                                 <td align="center">+0.50<br/>(n=79)</td>
                                 <td align="center">+0.85<br/>(n=82)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The proportion of patients with prolactin elevations â¥5x ULN was 0% for lurasidone hydrochloride-treated patients and 0.6% for placebo-treated patients. The proportion of female patients with prolactin elevations â¥5x ULN was 0% for lurasidone hydrochloride-treated patients and 1.3% for placebo-treated female patients. No male patients in the placebo or lurasidone hydrochloride treatment groups had prolactin elevations â¥5x ULN.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (6 to 17 years)</content>
                        </paragraph>
                        <paragraph>In a 104-week, open-label study of pediatric patients with bipolar depression, autistic disorder or another disorder, the median changes from baseline to endpoint in serum prolactin levels were -0.20 ng/mL (all patients), -0.30 ng/mL (females), and -0.05 ng/mL (males). The proportions of patients with a markedly high prolactin level (â¥5 times the upper limit of normal) at any time during open-label treatment were 2% (all patients), 3% (females), and 1% (males). </paragraph>
                        <paragraph>Adverse events among females in this trial that are potentially prolactin-related include galactorrhea (0.6%). Among male patients in this study, decreased libido was reported in one patient (0.2%) and there were no reports of impotence, gynecomastia, or galactorrhea.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_3bcfe14b-6741-4ff0-3487-cf641edd449a">
                     <id root="799b8767-a0d5-ca1f-b649-1c54c1a6083f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.8 Leukopenia, Neutropenia and Agranulocytosis</title>
                     <text>
                        <paragraph>Leukopenia/neutropenia Â has Â been Â reported Â during Â treatment Â with Â antipsychotic Â agents. Agranulocytosis (including fatal cases) has beenÂ reported with other agents in the class.</paragraph>
                        <paragraph>PossibleÂ riskÂ factorsÂ forÂ leukopenia/neutropeniaÂ includeÂ pre-existingÂ low whiteÂ bloodÂ cellÂ count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and lurasidone hydrochloride tablets should be discontinued at the first sign of decline in WBC, in the absence of other causative factors.Â </paragraph>
                        <paragraph>PatientsÂ withÂ neutropeniaÂ shouldÂ be carefullyÂ monitoredÂ forÂ feverÂ orÂ otherÂ symptomsÂ orÂ signsÂ of infectionÂ andÂ treatedÂ promptlyÂ ifÂ suchÂ symptomsÂ orÂ signsÂ occur.Â Patients withÂ severeÂ neutropenia (absoluteÂ neutrophilÂ countÂ &lt;1,000/mm<sup>3</sup>) shouldÂ discontinueÂ lurasidoneÂ hydrochloride tablets andÂ haveÂ theirÂ WBC followed until recovery. </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_e2e5a0af-303a-3a0d-9210-0cfc2550de00">
                     <id root="464e8dbf-8994-dac9-6dd4-2064a3151006"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.9 Orthostatic Hypotension and Syncope</title>
                     <text>
                        <paragraph>Lurasidone hydrochloride tablets may cause orthostatic hypotension and syncope, perhaps due to its Î±1-adrenergic receptor antagonism. Associated adverse reactions can include dizziness, lightheadedness, tachycardia, and bradycardia. Generally, these risks are greatest at the beginning Â  Â  of treatment and during dose escalation. Patients at increased risk of these adverse reactions or at increased risk of developingÂ complicationsÂ from hypotensionÂ includeÂ thoseÂ withÂ dehydration,Â hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, asÂ wellÂ asÂ patientsÂ whoÂ areÂ antipsychotic-naÃ¯ve.Â In suchÂ patients,Â considerÂ usingÂ aÂ lower starting dose and slower titration, and monitor orthostatic vital signs.</paragraph>
                        <paragraph>Orthostatic hypotension, as assessed by vital sign measurement, was defined by the following vitalÂ signÂ changes:Â â¥20Â mmÂ HgÂ decreaseÂ inÂ systolic bloodÂ pressureÂ andÂ â¥10Â bpmÂ increaseÂ in pulse fromÂ sitting to standing or supine to standing position.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar Depression </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, there were no reported adverse events of orthostatic hypotension and syncope.Â </paragraph>
                        <paragraph>OrthostaticÂ hypotension,Â asÂ assessedÂ byÂ vitalÂ signs,Â occurredÂ withÂ aÂ frequencyÂ of 0.6%Â with lurasidone hydrochloride 20 to 60 mg and 0.6% with lurasidone hydrochloride 80 to 120 mg compared to 0% with placebo.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or ValproateÂ </content>
                        </paragraph>
                        <paragraph>In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression therapy studies, Â there Â were Â no Â reported Â adverse Â events Â of Â orthostatic Â hypotension Â and Â syncope. OrthostaticÂ hypotension,Â asÂ assessedÂ byÂ vitalÂ signs,Â occurredÂ withÂ aÂ frequencyÂ of 1.1%Â with lurasidone hydrochloride 20 to 120 mg compared to 0.9% with placebo.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, there were no reported adverse events of orthostatic hypotension or syncope. </paragraph>
                        <paragraph>Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 1.1% with lurasidone hydrochloride 20 to 80 mg/day, compared to 0.6% with placebo.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_cf86d33f-1b8b-2aa4-d3a7-a903b8250f22">
                     <id root="7b8854d8-912e-b519-419f-8a5858445d46"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content>5.10  Falls</content>
                     </title>
                     <text>
                        <paragraph>Lurasidone hydrochloride may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_ed41df90-d40d-c9eb-0b43-4530aebb707f">
                     <id root="447bd51e-c62a-9d8f-4daf-d3b6e27f7b27"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.11 Seizures</title>
                     <text>
                        <paragraph>AsÂ withÂ otherÂ antipsychoticÂ drugs,Â lurasidoneÂ hydrochloride shouldÂ beÂ used cautiouslyÂ inÂ patientsÂ withÂ aÂ history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimerâs dementia. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar Depression</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>In the adult and pediatric 6-week, flexible-dose, placebo-controlled monotherapy bipolar depression studies, no patients experienced seizures/convulsions. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or Valproate</content>
                        </paragraph>
                        <paragraph>In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, no patient experienced seizures/convulsions.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_004a8873-7786-af88-121a-a17410c55cf9">
                     <id root="aa79b9b1-bbf7-1332-22c3-1f5b86ee827f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.12 Potential for Cognitive and Motor Impairment</title>
                     <text>
                        <paragraph>Lurasidone hydrochloride,Â likeÂ otherÂ antipsychotics, hasÂ theÂ potentialÂ toÂ impairÂ judgment,Â thinkingÂ orÂ motor skills.Â CautionÂ patients aboutÂ operatingÂ hazardousÂ machinery,Â including motorÂ vehicles,Â until they are reasonably certain that therapy with lurasidone hydrochloride tablets does not affect themÂ adversely.</paragraph>
                        <paragraph>In clinical studies with lurasidone hydrochloride, somnolence included: hypersomnia, hypersomnolence, sedation and somnolence.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar Depression </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>InÂ theÂ adult short-term,Â flexible-dosed, placebo-controlledÂ monotherapy bipolarÂ depressionÂ study, somnolence was reported by 7.3% (12/164) and 13.8%Â (23/167) with lurasidone hydrochloride 20 to 60 mg and 80 to 120 mg, respectively compared to 6.5% (11/168) of placebo patients.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or Valproate</content>
                        </paragraph>
                        <paragraph>In the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies, somnolence was reported by 11.4% (41/360) of patients treated with lurasidone hydrochloride 20 to 120 mg compared to 5.1% (17/334) of placebo patients.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (10 to 17 years) </content>
                        </paragraph>
                        <paragraph>In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, somnolence was reported by 11.4% (20/175) of patients treated with lurasidone hydrochloride 20 to 80 mg/day compared to 5.8% (10/172) of placebo treated patients.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_ed5bc472-3d28-0d5f-88ab-6532514c9729">
                     <id root="17aacafc-2c8c-c87a-2475-8deaeedbdf38"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.13 Body Temperature Dysregulation</title>
                     <text>
                        <paragraph>DisruptionÂ ofÂ theÂ bodyâsÂ abilityÂ toÂ reduceÂ core body temperatureÂ hasÂ beenÂ attributed to antipsychoticÂ agents. Â AppropriateÂ careÂ isÂ advisedÂ whenÂ prescribingÂ lurasidone hydrochloride tablets forÂ patientsÂ who will beÂ experiencingÂ conditionsÂ thatÂ mayÂ contributeÂ toÂ anÂ elevation inÂ coreÂ bodyÂ temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergicÂ activity, orÂ beingÂ subject toÂ dehydration.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_e9d908ad-c3e6-0fbc-323f-7b135f288087">
                     <id root="7e6ae508-82dc-bb3c-9a5a-d2d4e2962ad8"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.14 ActivationÂ ofÂ Mania/Hypomania</title>
                     <text>
                        <paragraph>AntidepressantÂ treatmentÂ canÂ increaseÂ theÂ risk ofÂ developingÂ aÂ manicÂ orÂ hypomanicÂ episode, particularly in Â patients Â with Â bipolar Â disorder. Â Monitor Â patients Â for Â the Â emergence Â of Â such episodes. Â  </paragraph>
                        <paragraph> InÂ the<content> adult</content>Â bipolarÂ depressionÂ monotherapyÂ andÂ adjunctiveÂ therapyÂ (withÂ lithiumÂ orÂ valproate)Â studies, less than 1% of subjects in the lurasidone hydrochloride and placebo groups developed manic or hypomanic episodes.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_74a16ccc-14fb-9a0d-fc1e-fca7db75266d">
                     <id root="2f9e3e07-572a-9565-5e19-6e60444162d5"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.15 Dysphagia</title>
                     <text>
                        <paragraph>Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. AspirationÂ pneumoniaÂ isÂ aÂ commonÂ causeÂ ofÂ morbidity andÂ mortalityÂ inÂ elderly patients,Â in particular those with advanced Alzheimerâs dementia. LurasidoneÂ hydrochloride tablets andÂ other antipsychoticÂ drugs should be used cautiously in patients at risk for aspiration pneumonia.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_64beb570-1cdd-50e1-e70e-ccbe9cfb7dc2">
                     <id root="b5315903-46e4-b28c-2111-2f41979ff70a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.16  Neurological Adverse Reactions in Patients with Parkinson&#146;s Disease or Dementia with Lewy Bodies</title>
                     <text>
                        <paragraph>Patients with Parkinsonâs Disease or Dementia with Lewy Bodies are reported to have an increasedÂ sensitivityÂ toÂ antipsychoticÂ medication.Â ManifestationsÂ ofÂ thisÂ increased sensitivity include   confusion,   obtundation,   postural   instability   with   frequent   falls,   extrapyramidal symptoms, and clinical features consistentÂ with the neuroleptic malignant syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ADVERSE_REACTIONS">
               <id root="9c16edc8-461f-1898-8538-e837115283ba"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions areÂ discussed in more detail in other sections of the labeling:Â </paragraph>
                  <list>
                     <item>Increased Mortality in Elderly Patients with Dementia-RelatedÂ PsychosisÂ <content styleCode="italics">[see</content>
                        <linkHtml href="#BOXED_WARNING">Boxed Warning</linkHtml>
                        <content styleCode="bold"/>
                        <content styleCode="italics"> and Warnings and Precautions</content>
                        <content styleCode="bold"/>
                        <linkHtml href="#_9a2c7fa4-f522-abb9-14e6-f251720c410d">(5.1</linkHtml>
                        <content styleCode="italics">)]</content>Â </item>
                     <item>Suicidal Thoughts and Behaviors <content styleCode="italics">[see </content>
                        <linkHtml href="#BOXED_WARNING">Boxed Warning</linkHtml>
                        <content styleCode="italics"> and Warnings and Precautions</content>
                        <content styleCode="bold"/>
                        <linkHtml href="#_f4c6c181-4e79-9e4b-fac8-30b76b163a6c">(5.2</linkHtml>
                        <content styleCode="italics">)]Â </content>
                     </item>
                     <item>Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-related Psychosis <content styleCode="italics">[see Warnings and Precautions</content>
                        <content styleCode="italics"> (</content>
                        <content styleCode="bold"/>
                        <linkHtml href="#_f7865b38-4a30-8823-3ad1-c93d6790b2a7">5.3</linkHtml>
                        <content styleCode="italics">)]Â </content>
                     </item>
                     <item>Neuroleptic Malignant SyndromeÂ <content styleCode="italics">[see Warnings and Precautions (</content>
                        <linkHtml href="#_2597bb6f-80c9-5f91-5c55-9068d1acbf85">5.4</linkHtml>
                        <content styleCode="italics">)]</content>Â </item>
                     <item>Tardive Dyskinesia <content styleCode="italics">[see Warnings and Precautions (</content>
                        <linkHtml href="#_cf40cc08-2a0c-7eca-6b2f-5883e42f251e">5.5</linkHtml>
                        <content styleCode="italics">)]</content>Â </item>
                     <item>Metabolic Changes <content styleCode="italics">[see Warnings and Precautions (</content>
                        <linkHtml href="#_728ef4cc-2114-48f5-157f-2cd238c2da9e">5.6</linkHtml>
                        <content styleCode="italics">)]</content>Â </item>
                     <item>HyperprolactinemiaÂ <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="bold"/>
                        <linkHtml href="#_bc1f52e9-67f4-8271-ff7e-e7cc04d8ec54">5.7</linkHtml>
                        <content styleCode="italics"> )]Â </content>
                     </item>
                     <item>Leukopenia, Neutropenia, and Agranulocytosis<content styleCode="italics">Â [see Warnings and Precautions (</content>
                        <content styleCode="bold"/>
                        <linkHtml href="#_3bcfe14b-6741-4ff0-3487-cf641edd449a">5.8</linkHtml>
                        <content styleCode="italics">)]</content>Â </item>
                     <item>Orthostatic Hypotension and Syncope<content styleCode="italics">Â [see Warnings and Precautions (</content>
                        <linkHtml href="#_e2e5a0af-303a-3a0d-9210-0cfc2550de00">5.9</linkHtml>
                        <content styleCode="italics">)]Â </content>
                     </item>
                     <item>Falls <content styleCode="italics">[see Warnings and PrecautionsÂ (</content>
                        <linkHtml href="#_cf86d33f-1b8b-2aa4-d3a7-a903b8250f22">5.10</linkHtml>
                        <content styleCode="italics">)]Â </content>
                     </item>
                     <item>Seizures <content styleCode="italics">[see Warnings and PrecautionsÂ (</content>
                        <linkHtml href="#_ed41df90-d40d-c9eb-0b43-4530aebb707f">5.11</linkHtml>
                        <content styleCode="italics">)]Â </content>
                     </item>
                     <item>Potential for Cognitive and Motor Impairment<content styleCode="italics">Â [see Warnings and Precautions (</content>
                        <linkHtml href="#_004a8873-7786-af88-121a-a17410c55cf9">5.12</linkHtml>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Body Temperature DysregulationÂ <content styleCode="italics">[see Warnings and Precautions (</content>
                        <linkHtml href="#_ed5bc472-3d28-0d5f-88ab-6532514c9729">5.13</linkHtml>
                        <content styleCode="italics">)]</content>Â </item>
                     <item>Activation of Mania/Hypomania<content styleCode="italics"> [see Warnings and Precautions (</content>
                        <linkHtml href="#_e9d908ad-c3e6-0fbc-323f-7b135f288087">5.14</linkHtml>
                        <content styleCode="italics">)]Â </content>
                     </item>
                     <item>Dysphagia<content styleCode="italics"> [see Warnings and Precautions (</content>
                        <linkHtml href="#_74a16ccc-14fb-9a0d-fc1e-fca7db75266d">5.15</linkHtml>
                        <content styleCode="italics">)]</content>Â </item>
                     <item>Neurological Adverse Reactions in Patients with Parkinsonâs Disease or Dementia with Lewy Bodies<content styleCode="italics"> [see Warnings and Precautions (</content>
                        <linkHtml href="#_64beb570-1cdd-50e1-e70e-ccbe9cfb7dc2">5.16</linkHtml>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>CommonlyÂ observedÂ adverseÂ reactionsÂ (incidenceÂ â¥Â 5%Â andÂ atÂ leastÂ twiceÂ the rateÂ forÂ placebo)Â wereÂ (<linkHtml href="#_9498837b-165d-9d5c-29fb-665e4deaba58">6.1</linkHtml>):</paragraph>
                        <list>
                           <item>Adult patients with bipolarÂ depression:Â akathisia,Â extrapyramidalÂ symptoms,Â and somnolence</item>
                           <item>Pediatric patients (10 to 17 years) with bipolar depression: nausea, weight increase, and insomnia.Â  </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold"> To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddyâs Laboratories, Inc. at 1-888-375-3784 Â or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.Â </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_9498837b-165d-9d5c-29fb-665e4deaba58">
                     <id root="37793c1e-3b41-0ce7-4da0-250eed101c73"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.1  Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.Â </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Adults</content>
                        </paragraph>
                        <paragraph>TheÂ informationÂ below isÂ derived from anÂ integratedÂ clinicalÂ studyÂ databaseÂ forÂ lurasidone hydrochloride consisting of 3,799 adult patients exposed to one or more doses of lurasidone hydrochloride for the treatment of bipolar depression and another indication in placebo-controlled studies. This experience corresponds withÂ aÂ totalÂ experienceÂ ofÂ 1,250.9 patient-years.Â AÂ totalÂ ofÂ 1,106Â lurasidone hydrochloride-treatedÂ patientsÂ hadÂ at least 24 weeks and 371 lurasidone hydrochloride-treated patients had at least 52 weeks of exposure.Â </paragraph>
                        <paragraph>Adverse events during exposure to study treatment were obtained by general inquiry and voluntarilyÂ reportedÂ adverseÂ experiences,Â asÂ wellÂ asÂ resultsÂ from physicalÂ examinations,Â vital signs, ECGs, weights and laboratory investigations. Adverse experiences were recorded by clinical investigators using their own terminology. In order to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Bipolar Depression (Monotherapy)</content>
                        </paragraph>
                        <paragraph>The following findings are based on the adult short-term, placebo-controlled premarketing study for bipolar depression in which lurasidone hydrochloride was administered at dailyÂ dosesÂ rangingÂ fromÂ 20Â toÂ 120 mg (n=331).Â </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">CommonlyÂ ObservedÂ AdverseÂ Reactions:Â </content>TheÂ mostÂ commonÂ adverseÂ reactionsÂ (incidenceÂ â¥5%, inÂ eitherÂ doseÂ group,Â andÂ atÂ leastÂ twiceÂ theÂ rateÂ ofÂ placebo)Â inÂ patientsÂ treatedÂ withÂ lurasidone hydrochloride were akathisia, extrapyramidal symptoms, somnolence, nausea, vomiting, diarrhea, and anxiety.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">AdverseÂ ReactionsÂ AssociatedÂ withÂ DiscontinuationÂ ofÂ Treatment:Â </content>A totalÂ ofÂ 6%Â (20/331) lurasidone hydrochloride-treated patients and 5.4% (9/168) of placebo-treated patients discontinued due to adverseÂ reactions.Â ThereÂ wereÂ noÂ adverseÂ reactions associatedÂ withÂ discontinuationÂ inÂ subjects treated with lurasidone hydrochloride that were at least 2% and at least twice the placebo rate.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride-Treated Patients:Â </content>Adverse reactions associated with the use of lurasidone hydrochloride (incidence of 2% or greater, rounded to theÂ nearestÂ percentÂ and lurasidoneÂ hydrochloride incidenceÂ greaterÂ thanÂ placebo)Â thatÂ occurredÂ duringÂ acute therapy (up to 6 weeks in patients with bipolar depression) are shown inÂ Table 20.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 20: Adverse Reactions in 2% or More of Lurasidone Hydrochloride-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Adult Short-term Monotherapy Bipolar Depression Study</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td align="left" rowspan="2">
                                    <content styleCode="bold">Body System or Organ Class</content>
                                    <br/>Dictionary-derived Term</td>
                                 <td colspan="4">
                                    <content styleCode="bold">Percentage of Patients Reporting Reaction</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">(N=168)</content>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Lurasidone</content>
                                    <content styleCode="bold">Hydrochloride</content>
                                    <content styleCode="bold">20 to 60 mg/day</content>
                                    <content styleCode="bold">(N=164)</content>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Lurasidone</content>
                                    <content styleCode="bold">Hydrochloride</content>
                                    <content styleCode="bold">80 to 120 mg/day</content>
                                    <content styleCode="bold">(N=167)</content>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">All</content>
                                    <content styleCode="bold">Lurasidone</content>
                                    <content styleCode="bold">Hydrochloride</content>
                                    <content styleCode="bold">(N=331)</content>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">Gastrointestinal</content>
                                    <content styleCode="bold"> Disorders</content>
                                 </td>
                                 <td/>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td align="left">Nausea</td>
                                 <td>8</td>
                                 <td>10</td>
                                 <td>17</td>
                                 <td>14</td>
                              </tr>
                              <tr>
                                 <td align="left">Dry Mouth</td>
                                 <td>4</td>
                                 <td>6</td>
                                 <td>4</td>
                                 <td>5</td>
                              </tr>
                              <tr>
                                 <td align="left">Vomiting</td>
                                 <td>2</td>
                                 <td>2</td>
                                 <td>6</td>
                                 <td>4</td>
                              </tr>
                              <tr>
                                 <td align="left">Diarrhea</td>
                                 <td>2</td>
                                 <td>5</td>
                                 <td>3</td>
                                 <td>4</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <content styleCode="bold">Infections and Infestations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Nasopharyngitis</td>
                                 <td>1</td>
                                 <td>4</td>
                                 <td>4</td>
                                 <td>4</td>
                              </tr>
                              <tr>
                                 <td align="left">Influenza</td>
                                 <td>1</td>
                                 <td>&lt;1</td>
                                 <td>2</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td align="left">Urinary Tract Infection</td>
                                 <td>&lt;1</td>
                                 <td>2</td>
                                 <td>1</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <content styleCode="bold">Musculoskeletal and</content>
                                    <content styleCode="bold"> Connective Tissue</content>
                                    <content styleCode="bold">Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Back Pain</td>
                                 <td>&lt;1</td>
                                 <td>3</td>
                                 <td>&lt;1</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <content styleCode="bold">Nervous System</content>
                                    <content styleCode="bold"> Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Extrapyramidal Symptoms*</td>
                                 <td>2</td>
                                 <td>5</td>
                                 <td>9</td>
                                 <td>7</td>
                              </tr>
                              <tr>
                                 <td align="left">Akathisia</td>
                                 <td>2</td>
                                 <td>8</td>
                                 <td>11</td>
                                 <td>9</td>
                              </tr>
                              <tr>
                                 <td align="left">Somnolence**</td>
                                 <td>7</td>
                                 <td>7</td>
                                 <td>14</td>
                                 <td>11</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <content styleCode="bold">Psychiatric Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Anxiety</td>
                                 <td>1</td>
                                 <td>4</td>
                                 <td>5</td>
                                 <td>4</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Note: FiguresÂ rounded to theÂ nearest integer</paragraph>
                        <paragraph>* ExtrapyramidalÂ symptomsÂ includeÂ adverseÂ event terms: bradykinesia,Â cogwheelÂ rigidity, drooling, dystonia, extrapyramidal disorder,Â glabellarÂ reflex abnormal,Â hypokinesia,Â muscle rigidity, oculogyric crisis,Â oromandibularÂ dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus</paragraph>
                        <paragraph>**Somnolence includes adverse event terms:Â hypersomnia,Â hypersomnolence,Â sedation, and somnolence </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Dose-Related Adverse Reactions in the Monotherapy Study:</content>
                        </paragraph>
                        <paragraph>In the adult short-term, placebo-controlled study (involving lower and higher lurasidone hydrochloride dose ranges) <content styleCode="italics">[seeÂ ClinicalÂ Studies</content>Â (<content styleCode="bold">
                              <linkHtml href="#_d711956a-c8d2-2fb5-6914-2fc9cce2952e">14.2</linkHtml>
                           </content>)]Â theÂ adverseÂ reactionsÂ thatÂ occurredÂ withÂ aÂ greaterÂ thanÂ 5% incidence inÂ theÂ patientsÂ treatedÂ withÂ lurasidone hydrochlorideÂ inÂ anyÂ doseÂ groupÂ andÂ greaterÂ thanÂ placeboÂ in bothÂ groups were nausea (10.4%, 17.4%), somnolence (7.3%, 13.8%), akathisia (7.9%, 10.8%), and extrapyramidal symptomsÂ (4.9%, 9%) for lurasidone hydrochloride 20 to 60 mg/day and lurasidone hydrochloride 80 to 120 mg/day, respectively.Â </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Bipolar Depression</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Adjunctive Therapy with Lithium or Valproate</content>
                        </paragraph>
                        <paragraph>The following findings are based on two adult short-term, placebo-controlled premarketing studies for bipolar depression in which lurasidone hydrochloride was administered atÂ dailyÂ dosesÂ rangingÂ fromÂ 20Â toÂ 120 mg as adjunctive therapy with lithium or valproate (n=360).Â </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">CommonlyÂ ObservedÂ AdverseÂ Reactions:Â </content>
                        </paragraph>
                        <paragraph>TheÂ mostÂ commonÂ adverseÂ reactionsÂ (incidenceÂ â¥5% and at least twice the rate of placebo) in subjectsÂ treatedÂ withÂ lurasidoneÂ hydrochloride wereÂ akathisiaÂ and somnolence.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">AdverseÂ ReactionsÂ AssociatedÂ withÂ DiscontinuationÂ ofÂ Treatment:</content>Â AÂ totalÂ ofÂ 5.8%Â (21/360) lurasidone hydrochloride-treated patients and 4.8% (16/334) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with lurasidone hydrochloride that were at least 2% and at least twice the placebo rate.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride-Treated Patients:</content>Â Adverse reactions associated with the use of lurasidone hydrochloride (incidence of 2% or greater, rounded to theÂ nearestÂ percentÂ and lurasidoneÂ hydrochloride incidenceÂ greaterÂ thanÂ placebo)Â thatÂ occurredÂ duringÂ acute therapy (up to 6 weeks in patients with bipolar depression) are shown inÂ Table 21.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 21: Adverse Reactions in 2% or More of Lurasidone Hydrochloride-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Adult Short-term Adjunctive Therapy Bipolar Depression Studies</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">Body System or Organ Class </content>
                                    <content styleCode="bold">
                                       <br/>Dictionary-derived Term</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">Percentage of Patients Reporting Reaction</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>(N=334)</content>
                                    <content styleCode="bold"> (%)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Lurasidone</content>
                                    <content styleCode="bold">Hydrochloride</content>
                                    <content styleCode="bold"> 20 to 120 mg/day</content>
                                    <content styleCode="bold">
                                       <br/>(N=360)</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Gastrointestinal Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Nausea</td>
                                 <td>10</td>
                                 <td>14</td>
                              </tr>
                              <tr>
                                 <td align="left">Vomiting</td>
                                 <td>1</td>
                                 <td>4</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">General Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Fatigue</td>
                                 <td>1</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Infections and Infestations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Nasopharyngitis</td>
                                 <td>2</td>
                                 <td>4</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Investigations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Weight Increased</td>
                                 <td>&lt;1</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Metabolism and Nutrition Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Increased Appetite</td>
                                 <td>1</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Nervous System Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Extrapyramidal Symptoms*</td>
                                 <td>9</td>
                                 <td>14</td>
                              </tr>
                              <tr>
                                 <td align="left">Somnolence**</td>
                                 <td>5</td>
                                 <td>11</td>
                              </tr>
                              <tr>
                                 <td align="left">Akathisia</td>
                                 <td>5</td>
                                 <td>11</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Psychiatric Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Restlessness</td>
                                 <td>&lt;1</td>
                                 <td>4</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Note: FiguresÂ rounded to theÂ nearest integer</paragraph>
                        <paragraph>* ExtrapyramidalÂ symptomsÂ includeÂ adverseÂ event terms: bradykinesia, cogwheelÂ rigidity, Â drooling,Â dystonia, extrapyramidal disorder,Â glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibularÂ dystonia,Â parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus</paragraph>
                        <paragraph>**Somnolence includes adverse event terms: hypersomnia,Â hypersomnolence,Â sedation, and somnolence </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Bipolar Depression</content>
                        </paragraph>
                        <paragraph>The following findings are based on the 6-week, placebo-controlled study for bipolar depression in pediatric patients 10 to 17 years in which lurasidone hydrochloride was administered at daily doses ranging from 20 to 80 mg (N=175). </paragraph>
                        <paragraph>
                           <content styleCode="italics">Commonly Observed Adverse Reactions</content>: The most common adverse reactions (incidence â¥5%, and at least twice the rate of placebo) in pediatric patients (10 to 17 years) treated with lurasidone hydrochloride were nausea, weight increase, and insomnia. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adverse Reactions Associated with Discontinuation of Treatment: </content>The incidence of discontinuation due to adverse reactions between lurasidone hydrochloride- and placebo-treated pediatric patients 10 to 17 years was 2% and 2%, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride-Treated Patients</content>:Â Adverse reactions associated with the use of lurasidone hydrochloride (incidence of 2% or greater, rounded to the nearest percent and lurasidone hydrochloride incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in pediatric patients with bipolar depression) are shown in Table 23. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 23: Adverse Reactions in 2% or More of </content>
                           <content styleCode="bold">Lurasidone Hydrochloride-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the 6</content>
                           <content styleCode="bold">â</content>
                           <content styleCode="bold">Week Bipolar Depression Study in Pediatric Patients (10 to 17 </content>
                           <content styleCode="bold">y</content>
                           <content styleCode="bold">ears)</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <thead>
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="bold">Body </content>
                                    <content styleCode="bold">S</content>
                                    <content styleCode="bold">ystem or Organ Class</content>
                                    <content styleCode="bold">
                                       <br/>Dictionary-derived Term</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">Percentage of Patients Reporting Reaction</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>(N=172)</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Lurasidone </content>
                                    <content styleCode="bold">H</content>
                                    <content styleCode="bold">ydrochloride</content>
                                    <content styleCode="bold">
                                       <br/>20 to 80 mg/day</content>
                                    <content styleCode="bold">
                                       <br/>(N=175)</content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody align="center">
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Gastrointestinal Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Nausea </td>
                                 <td>6</td>
                                 <td>16</td>
                              </tr>
                              <tr>
                                 <td align="left">Vomiting </td>
                                 <td>4</td>
                                 <td>6</td>
                              </tr>
                              <tr>
                                 <td align="left">Abdominal Pain Upper</td>
                                 <td>2</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td align="left">Diarrhea</td>
                                 <td>2</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td align="left">Abdominal Pain</td>
                                 <td>1</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">General Disorders And Administration Site Conditions </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Fatigue </td>
                                 <td>2</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Investigations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Weight Increased</td>
                                 <td>2</td>
                                 <td>7</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Metabolism and Nutrition Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Decreased Appetite</td>
                                 <td>2</td>
                                 <td>4</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Nervous System Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Somnolence*</td>
                                 <td>6</td>
                                 <td>11</td>
                              </tr>
                              <tr>
                                 <td align="left">Extrapyramidal symptoms**</td>
                                 <td>5</td>
                                 <td>6</td>
                              </tr>
                              <tr>
                                 <td align="left">Dizziness</td>
                                 <td>5</td>
                                 <td>6</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Psychiatric Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Insomnia</td>
                                 <td>2</td>
                                 <td>5</td>
                              </tr>
                              <tr>
                                 <td align="left">Abnormal Dreams</td>
                                 <td>2</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Oropharyngeal Pain</td>
                                 <td>2</td>
                                 <td>2</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Note: Figures rounded to the nearest integer </paragraph>
                        <paragraph>*Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence </paragraph>
                        <paragraph>**EPS includes adverse event terms: akathisia, cogwheel rigidity, dyskinesia, dystonia, hyperkinesia, joint stiffness, muscle rigidity, muscle spasms, musculoskeletal stiffness, oculogyric crisis, parkinsonism, tardive dyskinesia, and tremor</paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Extrapyramidal Symptoms</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar Depression </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>In the adult short-term, placebo-controlled monotherapy bipolar depression study, for lurasidone hydrochloride-treated patients, the incidence of reported events related to EPS, excluding akathisia and restlessness was 6.9% and 2.4% for placebo-treated patients. The incidence of akathisia for lurasidone hydrochloride-treated patients was 9.4% and 2.4% for placebo-treated patients. Incidence of EPS by dose groups is provided in Table 26.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 26: Incidence of EPS Compared to Placebo in the Adult Monotherapy Bipolar Depression Study</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <thead>
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">Adverse Event Term </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(N=168)</content>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                                 <td align="center" colspan="2">
                                    <content styleCode="bold">Lurasidone Hydrochloride</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td/>
                                 <td align="center">
                                    <content styleCode="bold">20 to 60 mg/day <br/>(N=164)</content>
                                    <content styleCode="bold">
                                       <br/>(%) </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">80 to </content>
                                    <content styleCode="bold">120 mg/day </content>
                                    <content styleCode="bold">
                                       <br/>(N=167)</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody align="center">
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">All EPS events </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">5 </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">12 </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">20</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">All EPS events, excluding Akathisia/Restlessness </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">2 </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">5 </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">9</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Akathisia </td>
                                 <td>2</td>
                                 <td>8</td>
                                 <td>11</td>
                              </tr>
                              <tr>
                                 <td align="left">Dystonia* </td>
                                 <td>0 </td>
                                 <td>0 </td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td align="left">Parkinsonism** </td>
                                 <td>2 </td>
                                 <td>5 </td>
                                 <td>8</td>
                              </tr>
                              <tr>
                                 <td align="left">Restlessness </td>
                                 <td>&lt;1 </td>
                                 <td>0 </td>
                                 <td>3</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Note: FiguresÂ rounded to theÂ nearest integer</paragraph>
                        <paragraph>*Dystonia includes adverse event terms: dystonia,Â oculogyricÂ crisis,Â oromandibularÂ dystonia, tongue spasm, torticollis, and trismus</paragraph>
                        <paragraph>**Â ParkinsonismÂ includesÂ adverseÂ eventÂ terms:Â bradykinesia, cogwheelÂ rigidity, drooling,Â extrapyramidal disorder, glabellarÂ reflex abnormal, hypokinesia, muscle rigidity,Â parkinsonism,Â psychomotorÂ retardation, and tremor</paragraph>
                        <paragraph>
                           <content styleCode="italics">Â Adjunctive Therapy with Lithium or Valproate</content>
                        </paragraph>
                        <paragraph>Â In Â the Â adult short-term, Â placebo-controlled Â adjunctive Â therapy Â bipolar Â depression Â studies, Â for lurasidone hydrochloride-treated patients, the incidence of EPS, excluding akathisia and restlessness, was 13.9%Â andÂ 8.7%Â forÂ placebo.Â TheÂ incidenceÂ ofÂ akathisiaÂ forÂ lurasidone hydrochloride-treatedÂ patientsÂ was 10.8% and 4.8% for placebo-treated patients. Incidence of EPS is provided inÂ Table 27.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 27: Incidence of EPS Compared to Placebo in the Adult Adjunctive Therapy Bipolar Depression Studies</content>
                        </paragraph>
                        <table border="1" cellpadding="3" width="85%">
                           <caption/>
                           <thead>
                              <tr>
                                 <th>Adverse Event Term</th>
                                 <th>PlaceboÂ <br/> (N=334)Â  <br/>(%)</th>
                                 <th>Lurasidone <br/>HydrochlorideÂ  <br/>20 to 120 mg/day<br/> (N=360)<br/>Â  (%)</th>
                              </tr>
                              <tr>
                                 <th align="left">All EPS events</th>
                                 <th>13</th>
                                 <th>24</th>
                              </tr>
                              <tr>
                                 <th align="left">All EPS events, excluding Akathisia/Restlessness</th>
                                 <th>9</th>
                                 <th>14</th>
                              </tr>
                           </thead>
                           <tbody align="center">
                              <tr>
                                 <td align="left">Akathisia </td>
                                 <td align="center">5 </td>
                                 <td align="center">11 </td>
                              </tr>
                              <tr>
                                 <td align="left">Dystonia* </td>
                                 <td>&lt;1 </td>
                                 <td>1 </td>
                              </tr>
                              <tr>
                                 <td align="left">Parkinsonism** </td>
                                 <td>8 </td>
                                 <td>13 </td>
                              </tr>
                              <tr>
                                 <td align="left">Restlessness </td>
                                 <td>&lt;1 </td>
                                 <td>4 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Note: FiguresÂ rounded to theÂ nearest integer</paragraph>
                        <paragraph>*Dystonia includes adverse event terms: dystonia,Â oculogyricÂ crisis,Â oromandibularÂ dystonia, tongue spasm, Â torticollis, and trismus</paragraph>
                        <paragraph>**Â ParkinsonismÂ includesÂ adverseÂ eventÂ terms:Â bradykinesia, cogwheelÂ rigidity, drooling,Â extrapyramidal disorder, glabellarÂ reflex abnormal, hypokinesia, muscle rigidity,Â parkinsonism,Â psychomotorÂ retardation, and tremorÂ </paragraph>
                        <paragraph>InÂ theÂ short-term,Â placebo-controlledÂ bipolar depression studies,Â dataÂ was objectively collected on the Simpson Angus Rating Scale (SAS) for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (BAS) for akathisia and the Abnormal Involuntary Movement Scale (AIMS) for dyskinesias.Â </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>In the 6-week, placebo-controlled study of bipolar depression in pediatric patients 10 to 17 years, the incidence of EPS, excluding events related to akathisia, for lurasidone hydrochloride-treated patients was similar in the lurasidone hydrochloride 20 to 80 mg/day (3.4%) treatment group vs. placebo (3.5%); and the incidence of akathisia-related events for lurasidone hydrochloride-treated patients was 2.9% vs. 3.5% for placebo-treated patients. Incidence of EPS by dose is provided in Table 28. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 28: Incidence of EPS Compared to Placebo in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <thead>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Adverse Event Term</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Placebo<br/>
                                    </content>
                                    <content styleCode="bold">(N=172)</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Lurasidone Hydrochloride</content>
                                    <content styleCode="bold">
                                       <br/>20 to 80 mg/day</content>
                                    <content styleCode="bold">
                                       <br/>(N=175)</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody align="center">
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">All EPS events*</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">5</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">6</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">All EPS events, excluding Akathisia/Restlessness</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">4</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">3</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Akathisia</td>
                                 <td>
                                    <content styleCode="bold">4</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">3</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Parkinsonism**</td>
                                 <td>&lt;1</td>
                                 <td>&lt;1</td>
                              </tr>
                              <tr>
                                 <td align="left">Dystonia***</td>
                                 <td>1</td>
                                 <td>&lt;1</td>
                              </tr>
                              <tr>
                                 <td align="left">Salivary hypersecretion</td>
                                 <td>&lt;1</td>
                                 <td>&lt;1</td>
                              </tr>
                              <tr>
                                 <td align="left">Psychomotor hyperactivity</td>
                                 <td>0</td>
                                 <td>&lt;1</td>
                              </tr>
                              <tr>
                                 <td align="left">Tardive Dyskinesia</td>
                                 <td>&lt;1</td>
                                 <td>0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Note: Figures rounded to the nearest integer </paragraph>
                        <paragraph>* EPS include adverse event terms: akathisia, cogwheel rigidity, dyskinesia, dystonia, hyperkinesia, joint stiffness, muscle rigidity, muscle spasms, musculoskeletal stiffness, oculogyric crisis, parkinsonism, tardive dyskinesia, and tremor </paragraph>
                        <paragraph>** Parkinsonism includes adverse event terms: bradykinesia, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, parkinsonism, and psychomotor retardation </paragraph>
                        <paragraph>***Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus</paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar Depression </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>TheÂ meanÂ changeÂ from baselineÂ forÂ lurasidone hydrochloride-treatedÂ adultÂ patientsÂ forÂ theÂ SAS,Â BASÂ andÂ AIMSÂ was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormalÂ wasÂ greaterÂ inÂ lurasidone hydrochloride-treatedÂ patients andÂ placeboÂ forÂ theÂ BASÂ (lurasidone hydrochloride, 8.4%; placebo, 5.6%), the SAS (lurasidone hydrochloride, 3.7%; placebo, 1.9%) and the AIMS (lurasidone hydrochloride, 3.4%; placebo, 1.2%).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or Valproate</content>
                        </paragraph>
                        <paragraph>TheÂ meanÂ changeÂ from baselineÂ forÂ lurasidone hydrochloride-treatedÂ adult patientsÂ forÂ theÂ SAS,Â BASÂ andÂ AIMSÂ was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormalÂ wasÂ greaterÂ inÂ lurasidone hydrochloride-treatedÂ patients andÂ placeboÂ forÂ theÂ BASÂ (lurasidone hydrochloride, 8.7%; placebo, 2.1%), the SAS (lurasidone hydrochloride, 2.8%; placebo, 2.1%) and the AIMS (lurasidone hydrochloride, 2.8%; placebo, 0.6%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>The mean change from baseline for lurasidone hydrochloride-treated pediatric patients 10 to 17 years with bipolar depression for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone hydrochloride-treated patients and placebo for the BAS (lurasidone hydrochloride, 4.6%; placebo, 2.4%), the SAS (lurasidone hydrochloride, 0.6%; placebo, 0%) and was the same for the AIMS (lurasidone hydrochloride, 0%; placebo, 0%).</paragraph>
                        <paragraph>
                           <content styleCode="italics underline">DystoniaÂ </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Class Effect:</content> Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. Â While these symptoms can occur atÂ lowÂ doses,Â theyÂ occurÂ moreÂ frequentlyÂ andÂ withÂ greaterÂ severityÂ withÂ highÂ potencyÂ andÂ at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.Â Â Â Â Â Â Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar Depression </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, dystonia occurred in 0.9% of lurasidone hydrochloride-treated subjects (0% and 1.8% for lurasidone hydrochloride 20 to 60 mg/day and lurasidone hydrochloride 80 to 120 mg/day, respectively) compared to 0% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or Valproate</content>Â </paragraph>
                        <paragraph>In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, dystonia occurred in 1.1% of lurasidone hydrochloride-treated subjects (20 to 120 mg) compared to 0.6% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.Â </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, dystonia occurred in 0.6% of lurasidone hydrochloride-treated patients compared to 1.2% of patients receiving placebo. No patients discontinued the clinical study due to dystonic events.</paragraph>
                        <paragraph>
                           <content styleCode="underline"/>
                           <content styleCode="italics underline">Other Adverse Reactions Observed During the Premarketing Evaluation of Lurasidone Hydrochloride</content>
                        </paragraph>
                        <paragraph>Following is a list of adverse reactions reported by adult patients treated with lurasidone hydrochloride at multiple doses of â¥ 20 mg once daily within the premarketing database of 2,905 patients with another indication. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions that appear elsewhere in the lurasidone hydrochloride tablets label are not included. </paragraph>
                        <paragraph>Reactions are further categorized by organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (frequent) (only those not already listed in the tabulated results from placebo-controlled studies appear in this listing); those occurring in 1/100 to 1/1,000 patients (infrequent); and those occurring in fewer than 1/1,000 patients (rare).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and Lymphatic System Disorders</content>: <content styleCode="bold italics">Infrequent</content>
                           <content styleCode="bold">: </content>
                           <content styleCode="italics">anemia</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorders</content>: <content styleCode="bold italics">Frequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">tachycardia;</content>
                           <content styleCode="bold italics">Infrequent: </content>
                           <content styleCode="italics">AV block 1st degree, angina pectoris, bradycardia </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Ear and Labyrinth Disorders</content>: <content styleCode="bold italics">Infrequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">vertigo</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders</content>: <content styleCode="bold italics">Frequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">blurred vision</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders</content>:<content styleCode="bold italics"> Frequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">abdominal pain, diarrhea;</content>
                           <content styleCode="bold italics">Infrequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">gastritis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> General Disorders and Administrative Site Conditions</content>: <content styleCode="bold italics">Rare</content>
                           <content styleCode="bold">: </content>
                           <content styleCode="italics">sudden death</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations</content>: <content styleCode="bold italics">Frequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">CPK increased </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and Nutritional System Disorders</content>: <content styleCode="bold italics">Frequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">decreased appetite </content>Â  </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Musculoskeletal and Connective Tissue Disorders</content>: <content styleCode="bold italics">Rare</content>
                           <content styleCode="bold">: </content>
                           <content styleCode="italics">rhabdomyolysis </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders</content>: <content styleCode="bold italics">Infrequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">cerebrovascular accident, dysarthria</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders</content>: <content styleCode="bold italics">Infrequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">abnormal dreams, panic attack, sleep disorder </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Renal and Urinary Disorders</content>: <content styleCode="bold italics">Infrequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">dysuria;</content>
                           <content styleCode="bold italics">Rare:</content>
                           <content styleCode="italics"> renal failure </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Reproductive System and Breast Disorders</content>:<content styleCode="bold italics"> Infrequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">amenorrhea, dysmenorrhea;</content>
                           <content styleCode="bold italics">Rare:</content>
                           <content styleCode="italics">breast enlargement, breast pain, galactorrhea, erectile dysfunction , priapism</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders</content>: <content styleCode="bold italics">Frequent:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">rash, pruritus;</content>
                           <content styleCode="bold italics">Rare:</content>
                           <content styleCode="bold"/>
                           <content styleCode="italics">angioedema</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders</content>: <content styleCode="bold italics">Frequent:</content>
                           <content styleCode="italics"> hypertension Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Clinical Laboratory Changes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Bipolar DepressionÂ </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                           <content styleCode="italics underline"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">MonotherapyÂ </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">SerumÂ Creatinine</content>: In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depressionÂ study,Â theÂ meanÂ changeÂ from BaselineÂ inÂ serumÂ creatinine wasÂ +0.01Â mg/dLÂ for lurasidone hydrochloride-treatedÂ patients comparedÂ toÂ -0.02Â mg/dLÂ forÂ placebo-treatedÂ patients. AÂ creatinine shiftÂ from normalÂ toÂ highÂ occurredÂ inÂ 2.8%Â (9/322) ofÂ lurasidone hydrochloride-treatedÂ patients andÂ 0.6% (1/162) on placebo (Table 31).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 31: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adult Monotherapy Bipolar Depression Study</content>
                        </paragraph>
                        <table border="1" cellpadding="3" width="85%">
                           <caption/>
                           <tbody>
                              <tr align="center">
                                 <td>
                                    <content styleCode="bold">Laboratory Parameter</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">PlaceboÂ  </content>
                                    <br/>
                                    <content styleCode="bold">(N=168)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Lurasidone <br/>Hydrochloride <br/>20 to 60 mg/dayÂ  <br/>(N=164)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Lurasidone <br/>Hydrochloride <br/>80 to 120 mg/dayÂ  <br/>(N=167)</content>
                                 </td>
                              </tr>
                              <tr align="center">
                                 <td>Serum Creatinine Elevated</td>
                                 <td>&lt;1% </td>
                                 <td>2% </td>
                                 <td>4% </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or Valproate</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">SerumÂ Creatinine</content>: In adult short-term, placebo-controlled premarketing adjunctive studies for bipolar depression,Â theÂ meanÂ changeÂ from BaselineÂ inÂ serum creatinineÂ wasÂ +0.04Â mg/dLÂ forÂ lurasidone hydrochloride-treated patients compared to -0.01 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 4.3% (15/360) of lurasidone hydrochloride-treated patients and 1.6% (5/334) on placeboÂ (Table 32).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 32: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adult Adjunctive Therapy Bipolar Depression Studies</content>
                        </paragraph>
                        <table border="1" cellpadding="3" width="85%">
                           <caption/>
                           <tbody align="center">
                              <tr>
                                 <td>
                                    <content styleCode="bold">Laboratory Parameter</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">PlaceboÂ <br/> (N=334)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Lurasidone Hydrochloride<br/> 20 to 120 mg/day <br/> (N=360)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Serum Creatinine Elevated</td>
                                 <td>2% </td>
                                 <td>4% </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Serum Creatinine</content>: In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, the mean change from Baseline in serum creatinine was +0.021 mg/dL for lurasidone hydrochloride-treated patients compared to +0.009 mg/dL for placebo-treated patients. A creatinine shift from normal to high (based on the centralized laboratory definition) occurred in 6.7% (11/163) of lurasidone hydrochloride-treated patients and 4.5% (7/155) on placebo (Table 33). </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 33: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td>
                                    <content styleCode="bold">Laboratory Parameter</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>(N=155)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Lurasidone </content>
                                    <content styleCode="bold">H</content>
                                    <content styleCode="bold">ydrochloride</content>
                                    <content styleCode="bold">
                                       <br/>20 to 80 mg/day</content>
                                    <content styleCode="bold">
                                       <br/>(N=163)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">Serum Creatinine Elevated</content>
                                 </td>
                                 <td>4.5%</td>
                                 <td>6.7%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (6 to 17 years) </content>
                        </paragraph>
                        <paragraph>In a 104-week, open-label study in pediatric patients with bipolar depression, autistic disorder or another disorder, the mean change from baseline to Week 104 in serum creatinine was +0.07 mg/dL. In patients with a normal serum creatinine at baseline, 6% experienced a shift to high at endpoint.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_613263de-247f-18c4-d052-118009633389">
                     <id root="8ba262fe-2306-7c55-9bb0-00cf426beec6"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content> 6.2 Postmarketing Experience </content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of lurasidone hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Â  </paragraph>
                        <paragraph> Hypersensitivity Reactions: Urticaria, throat swelling, tongue swelling, dyspnea, and rash.</paragraph>
                        <paragraph>Metabolism and Nutrition Disorders: Hyponatremia</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DRUG_INTERACTIONS">
               <id root="0978cf7d-bd02-4e31-8ae3-011175012344"/>
               <code code="34073-7" displayName="DRUG INTERACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
               <component>
                  <section ID="_9033c447-94f5-8fa9-0509-3fa796995fe1">
                     <id root="c146a7e1-7a72-ba4c-a275-400d68f0635b"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.1             Drugs Having Clinically Important Interactions with Lurasidone Hydrochloride</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Table 34: Clinically Important Drug Interactions with Lurasidone Hydrochloride </content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td colspan="2">Â <content styleCode="bold">Strong CYP3A4 Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Clinical Impact:</td>
                                 <td> Concomitant use of lurasidone hydrochloride with strong CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of lurasidone hydrochloride alone <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>
                                    <content styleCode="italics">)]</content>. </td>
                              </tr>
                              <tr>
                                 <td>Intervention:</td>
                                 <td> Lurasidone hydrochloride should not be used concomitantly with strong CYP3A4 inhibitors <content styleCode="italics">[see Contraindications (</content>
                                    <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>
                                    <content styleCode="italics">)]</content>. </td>
                              </tr>
                              <tr>
                                 <td>Examples:</td>
                                 <td> Ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil</td>
                              </tr>
                              <tr>
                                 <td colspan="2">Â <content styleCode="bold">Moderate CYP3A4 Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Clinical Impact:</td>
                                 <td> Concomitant use of lurasidone hydrochloride with moderate CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of lurasidone hydrochloride alone <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>
                                    <content styleCode="italics">)]</content>. </td>
                              </tr>
                              <tr>
                                 <td>Intervention:</td>
                                 <td> Lurasidone hydrochloride dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 <content styleCode="italics">[see Dosage and Administration (</content>
                                    <linkHtml href="#_ae8945bb-e754-49f7-9b4b-31389ad53614">2.6</linkHtml>
                                    <content styleCode="italics">)]. </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Examples:</td>
                                 <td> Diltiazem, atazanavir, erythromycin, fluconazole, verapamil </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">Strong CYP3A4 Inducers</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> Clinical Impact: </td>
                                 <td> Concomitant use of lurasidone hydrochloride with strong CYP3A4 inducers decreased the exposure of lurasidone compared to the use of lurasidone hydrochloride alone <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> Intervention: </td>
                                 <td> Lurasidone hydrochloride should not be used concomitantly with strong CYP3A4 inducers <content styleCode="italics">[see Contraindications (</content>
                                    <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> Examples: </td>
                                 <td> Rifampin, avasimibe, St. Johnâs wort, phenytoin, carbamazepine </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">Moderate CYP3A4 Inducers</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> Clinical Impact: </td>
                                 <td> Concomitant use of lurasidone hydrochloride with moderate CYP3A4 inducers decreased the exposure of lurasidone compared to the use of lurasidone hydrochloride alone <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> Intervention: </td>
                                 <td> Lurasidone hydrochloride dose should be increased when used concomitantly with moderate inducers of CYP3A4 <content styleCode="italics">[see Dosage and Administration (</content>
                                    <linkHtml href="#_ae8945bb-e754-49f7-9b4b-31389ad53614">2.6</linkHtml>
                                    <content styleCode="italics">)</content>]. </td>
                              </tr>
                              <tr>
                                 <td> Examples: </td>
                                 <td> Bosentan, efavirenz, etravirine, modafinil, nafcillin </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_b9accee5-911c-f7f4-3077-b02d06e08c55">
                     <id root="ae086415-b52d-283a-326a-aa175590b8a4"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.2 <content>Drugs Having No Clinically Important Interactions with </content>
                        <content>Lurasidone Hydrochloride</content>
                     </title>
                     <text>
                        <paragraph>Based on pharmacokinetic studies, no dosage adjustment of lurasidone hydrochloride is required when administered concomitantly with lithium, valproate, or substrates of P-gp or CYP3A4 <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>
                           <content styleCode="italics">)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DRUG_ABUSE_AND_DEPENDENCE">
               <id root="6c756204-3ea0-28f8-5389-5b35ba1b763d"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>8   USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>â¢ Pregnancy: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure (<linkHtml href="#PREGNANCY">8.1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="PREGNANCY">
                     <id root="a003f9d0-3892-6711-39c7-c6fe02f69a32"/>
                     <code code="42228-7" displayName="PREGNANCY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lurasidone hydrochloride during pregnancy. For more information, contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit <content styleCode="underline">http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Risk Summary</content>
                        </paragraph>
                        <paragraph> Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery <content styleCode="italics">[see Clinical Considerations]</content>. There are no studies of lurasidone hydrochloride use in pregnant women. The limited available data are not sufficient to inform a drug-associated risk of birth defects or miscarriage. In animal reproduction studies, no teratogenic effects were seen in pregnant rats and rabbits given lurasidone during the period of organogenesis at doses approximately 1.5- and 6-times, the maximum recommended human dose (MRHD) of 160 mg/day, respectively based on mg/m<sup>2</sup>
                           <sup>Â </sup>body surface area <content styleCode="italics">[see Data]</content>. Â  </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="underline"> Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Â  </paragraph>
                        <paragraph>
                           <content styleCode="underline"> Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Animal Data</content>
                        </paragraph>
                        <paragraph> Pregnant rats were treated with oral lurasidone at doses of 3, 10, and 25 mg/kg/day during the period of organogenesis. These doses are 0.2, 0.6, and 1.5 times the MRHD of 160 mg/day based on mg/m<sup>2Â </sup>body surface area. No teratogenic or embryo-fetal effects were observed up to 1.5 times the MRHD of 160 mg/day, based on mg/m<sup>2</sup>. </paragraph>
                        <paragraph>Pregnant rabbits were treated with oral lurasidone at doses of 2, 10, and 50 mg/kg/day during the period of organogenesis. These doses are 0.2, 1.2 and 6 times the MRHD of 160 mg/day based on mg/m<sup>2</sup>. No teratogenic or embryo-fetal effects were observed up to 6 times the MRHD of 160 mg/day based on mg/m<sup>2</sup>. </paragraph>
                        <paragraph>Pregnant rats were treated with oral lurasidone at doses of 0.4, 2, and 10 mg/kg/day during the periods of organogenesis and lactation. These doses are 0.02, 0.1 and 0.6 times the MRHD of 160 mg/day based on mg/m<sup>2</sup>. No pre- and postnatal developmental effects were observed up to 0.6 times the MRHD of 160 mg/day, based on mg/m<sup>2</sup>.<sup>Â </sup>Â </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_60f8c01d-6acd-b7bb-ce30-b446fd3f2465">
                     <id root="da098b5c-b425-f1c8-2ae8-25e43d21df49"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content>8.2 Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph> Lactation studies have not been conducted to assess the presence of lurasidone in human milk, the effects on the breastfed infant, or the effects on milk production. Lurasidone is present in rat milk. The development and health benefits of breastfeeding should be considered along with the motherâs clinical need for lurasidone hydrochloride and any potential adverse effects on the breastfed infant from lurasidone hydrochloride or from the underlying maternal condition.   Â </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="PEDIATRIC_USE">
                     <id root="0baa27d6-538a-d8c3-faf7-6838443b7ebe"/>
                     <code code="34081-0" displayName="PEDIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Bipolar </content>
                           <content styleCode="italics">Depression</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of lurasidone hydrochloride 20 to 80 mg/day for the treatment of bipolar depression in pediatric patients (10 to 17 years) was established in a 6âweek, placeboâcontrolled clinical study in 347 pediatric patients <content styleCode="italics">[see Dosage and Administration (</content>
                           <linkHtml href="#_fdd5ef0e-2ec4-12e4-3c30-8583c4ee8ae9">2.2</linkHtml>
                           <content styleCode="italics">), Adverse Reactions (</content>
                           <linkHtml href="#_9498837b-165d-9d5c-29fb-665e4deaba58">6.1</linkHtml>
                           <content styleCode="italics">), and Clinical Studies (</content>
                           <linkHtml href="#_d711956a-c8d2-2fb5-6914-2fc9cce2952e">14.2</linkHtml>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of lurasidone hydrochloride tablets has not been established in pediatric patients less than 10 years of age with bipolar depression. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Irritability Associated with Autistic Disorder</content>
                        </paragraph>
                        <paragraph>The effectiveness of lurasidone hydrochloride tablets in pediatric patients for the treatment of irritability associated with autistic disorder has not been established. Â  </paragraph>
                        <paragraph> Efficacy was not demonstrated in a 6-week study evaluating lurasidone hydrochloride 20 mg/day and 60 mg/day for the treatment of pediatric patients 6 to 17 years of age with irritability associated with autistic disorder diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria. The primary objective of the study as measured by improvement from Baseline in the irritability subscale of the Aberrant Behavior Checklist (ABC) at Endpoint (Week 6) was not met. A total of 149 patients were randomized to lurasidone hydrochloride or placebo. Vomiting occurred at a higher rate than reported in other lurasidone hydrochloride studies (4/49 or 8% for 20mg, 14/51 or 27% for 60mg, and 2/49 or 4% for placebo), particularly in children ages 6 to 12 (13 out of 18 patients on lurasidone hydrochloride with vomiting).</paragraph>
                        <paragraph>In a long-term, open-label study that enrolled pediatric patients (age 6 to 17 years) with bipolar depression, autistic disorder or another disorder from three short-term, placebo-controlled trials, 54% (378/701) received lurasidone for 104 weeks. There was one adverse event in this trial that was considered possibly drug-related and has not been reported in adults receiving lurasidone: a 10 year old male experienced a prolonged, painful erection, consistent with priapism, that led to treatment discontinuation. </paragraph>
                        <paragraph>In this trial, the mean increase in height from open-label baseline to Week 104 was 4.94 cm. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of children and adolescents by comparisons to age- and sex-matched population standards. A z-score change &lt;0.5 SD is considered not clinically significant. In this trial, the mean change in height z-score from open-label baseline to Week 104 was +0.05 SD, indicating minimal deviation from the normal growth curve.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Juvenile animal studies</content>
                        </paragraph>
                        <paragraph> Adverse effects were seen on growth, physical and neurobehavioral development at doses as low as 0.2 times the MRHD based on mg/m<sup>2</sup>. Lurasidone was orally administered to rats from postnatal days 21 through 91 (this period corresponds to childhood, adolescence, and young adulthood in humans) at doses of 3, 30, and 150 (males) or 300 (females) mg/kg/day which are 0.2 to 10 times (males) and 20 times (females) the maximum recommended adult human dose (MRHD) of 160 mg/day based on mg/m<sup>2</sup>. The adverse effects included dose-dependent decreases in femoral length, bone mineral content, body and brain weights at 2 times the MRHD in both sexes, and motor hyperactivity at 0.2 and 2 times the MRHD in both sexes based on mg/m<sup>2</sup>. In females, there was a delay in attainment of sexual maturity at 2 times the MRHD, associated with decreased serum estradiol. Mortality occurred in both sexes during early post-weaning period and some of the male weanlings died after only 4 treatments at doses as low as 2 times the MRHD based on mg/m<sup>2</sup>. Histopathological findings included increased colloid in the thyroids and inflammation of the prostate in males at 10 times MRHD based on mg/m<sup>2 </sup>and mammary gland hyperplasia, increased vaginal mucification, and increased ovarian atretic follicles at doses as low as 0.2 times the MRHD based on mg/m<sup>2</sup>. Some of these findings were attributed to transiently elevated serum prolactin which was seen in both sexes at all doses. However, there were no changes at any dose level in reproductive parameters (fertility, conception indices, spermatogenesis, estrous cycle, gestation length, parturition, number of pups born). The no effect dose for neurobehavioral changes in males is 0.2 times the MRHD based on mg/m<sup>2 </sup>and could not be determined in females. The no effect dose for growth and physical development in both sexes is 0.2 times the MRHD based on mg/m<sup>2</sup>. Â  </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="GERIATRIC_USE">
                     <id root="54671b20-c7b6-a489-aa18-8eb92180c481"/>
                     <code code="34082-8" displayName="GERIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>ClinicalÂ studiesÂ withÂ lurasidone hydrochloride Â didÂ notÂ include sufficientÂ numbers ofÂ patientsÂ agedÂ 65Â andÂ older toÂ determineÂ whetherÂ orÂ notÂ theyÂ respondÂ differentlyÂ from youngerÂ patients.Â InÂ elderlyÂ patients with psychosis (65 to 85), lurasidone hydrochlorideÂ concentrations (20 mg/day) were similar to those in young subjects. It is unknown whether dose adjustment is necessary on the basis of age alone. Â  </paragraph>
                        <paragraph> ElderlyÂ patientsÂ withÂ dementia-relatedÂ psychosis treatedÂ withÂ lurasidone hydrochloride Â areÂ atÂ anÂ increased risk of death compared to placebo. Lurasidone hydrochloride tablets are not approved for the treatment of patients with dementia-related psychosis <content styleCode="italics">[see </content>
                           <linkHtml href="#BOXED_WARNING">Boxed Warning</linkHtml>
                           <content styleCode="italics">, Warnings and Precautions (</content>
                           <linkHtml href="#_9a2c7fa4-f522-abb9-14e6-f251720c410d">5.1</linkHtml>
                           <content styleCode="italics">, </content>
                           <linkHtml href="#_f7865b38-4a30-8823-3ad1-c93d6790b2a7">5.3</linkHtml>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_835b2b82-75f8-8a61-729c-d8c451263468">
                     <id root="d826f624-febc-36b1-f80a-67dfc7438a03"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Reduce the maximum recommended dosage in patients with moderate or severe renal impairment (CLcr&lt;50 mL/minute). Patients with impaired renal function (CLcr&lt;50 mL/minute) had higher exposure to lurasidone than patients with normal renal function <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>
                           <content styleCode="italics">)]</content>. Greater exposure may increase the risk of lurasidone hydrochloride-associated adverse reactions <content styleCode="italics">[see Dosage and Administration</content> (<linkHtml href="#_83721e04-563e-b6d4-eb60-19c19c0bf51f">2.4</linkHtml>)] </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_40719355-d475-9dc7-d086-6e7986c31c1b">
                     <id root="b64bbd1f-5e54-ec83-f4ca-0223d4397115"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content>8.7 Hepatic Impairment </content>
                     </title>
                     <text>
                        <paragraph>Reduce the maximum recommended dosage in patients with moderate to severe hepatic impairment (Child-Pugh score â¥7). Patients with moderate to severe hepatic impairment (Child-Pugh score â¥7) generally had higher exposure to lurasidone than patients with normal hepatic function <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>
                           <content styleCode="italics">)]</content>. Greater exposure may increase the risk of lurasidone hydrochloride-associated adverse reactions <content styleCode="italics">[see Dosage and Administration (</content>
                           <linkHtml href="#_7816ac27-85cb-5181-8780-5bd594b8b4f1">2.5</linkHtml>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_57c65ff8-fcdd-dad2-441e-7826f29ac234">
                     <id root="6b4fde70-d2f3-2f1d-d9dd-1ff7426ed3dc"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content>8.8 Other Specific Populations</content>
                     </title>
                     <text>
                        <paragraph>No dosage adjustment for lurasidone hydrochloride is required on the basis of a patientâs sex, race, or smoking status <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>
                           <content styleCode="italics">)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_68186d3e-c921-a861-f926-ee3203febe04">
               <id root="14ab62e4-9bbb-2c7d-9328-87a1ad9f9676"/>
               <code code="42227-9" displayName="DRUG ABUSE AND DEPENDENCE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20250225"/>
               <component>
                  <section ID="_8a4d44d2-70d4-d2e3-cc03-a73f98035286">
                     <id root="599569ca-a4ed-78a9-dc3c-92f35a7ba0d5"/>
                     <code code="34085-1" displayName="CONTROLLED SUBSTANCE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>9.1 ControlledÂ Substance</title>
                     <text>
                        <paragraph>Lurasidone hydrochloride is not a controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_4edca69e-5839-1866-e2b7-5f9de779eed5">
                     <id root="b7d1318a-94ac-90ed-1290-d866c010fb4a"/>
                     <code code="34086-9" displayName="ABUSE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Lurasidone hydrochloride has not been systematically studied in humans forÂ its potential for abuse or physical dependence or its ability to induceÂ tolerance. WhileÂ clinicalÂ studiesÂ withÂ lurasidoneÂ hydrochloride tabletsÂ didÂ notÂ reveal any tendency for drug-seeking behavior, these observations were not systematic and it is not possibleÂ toÂ predictÂ theÂ extentÂ toÂ whichÂ aÂ CNS-activeÂ drugÂ willÂ beÂ misused,Â divertedÂ and/or abusedÂ onceÂ itÂ isÂ marketed.Â PatientsÂ shouldÂ beÂ evaluatedÂ carefullyÂ forÂ aÂ historyÂ ofÂ drugÂ abuse, and such patients should be observed carefully for signs of lurasidone hydrochloride tabletsÂ misuse or abuse (e.g., development of tolerance, drug-seeking behavior, increases in dose).</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_85d9862b-4f51-77ec-62fd-ff967e96a8b2">
               <id root="45298602-06fe-d3b7-0f9b-6536cd506edd"/>
               <code code="34088-5" displayName="OVERDOSAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>10  OVERDOSAGE </title>
               <effectiveTime value="20250225"/>
               <component>
                  <section ID="_712c5dbe-b12b-c702-13f8-8c8b045381e0">
                     <id root="f570a692-8fa5-aad2-b7bf-377a02ed9c71"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>10.1 HumanÂ Experience</title>
                     <text>
                        <paragraph>InÂ premarketingÂ clinicalÂ studies, accidentalÂ orÂ intentionalÂ overdosageÂ ofÂ lurasidoneÂ hydrochloride wasÂ identified in one patient who ingested an estimated 560 mg of lurasidone hydrochloride. This patient recovered without sequelae. This patient resumed lurasidone hydrochloride treatment for an additional two months.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="_3fc496bb-f589-04c6-21b9-eae3c8d6e2cb">
                     <id root="6a6ee144-daa4-6674-db74-3a7b7d1ebc55"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>10.2  Management of Overdosage</title>
                     <text>
                        <paragraph> No specific antidotes for lurasidone hydrochloride tablets are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an overdose occurs, consult a Certified Poison Control Center (1-800-222-1222 or www.poison.org). Â </paragraph>
                        <paragraph>Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects whenÂ administeredÂ in patientsÂ withÂ anÂ acuteÂ overdoseÂ of lurasidone hydrochloride. Similarly,Â theÂ alpha-blocking properties of bretyliumÂ mightÂ beÂ additive toÂ thoseÂ ofÂ lurasidone hydrochloride, resultingÂ inÂ problematicÂ hypotension.</paragraph>
                        <paragraph> Hypotension and circulatory collapse should be treated with appropriate measures. Epinephrine and dopamine should not be used, or other sympathomimetics with beta-agonist activity, since betaÂ stimulation mayÂ worsenÂ hypotensionÂ inÂ the settingÂ ofÂ lurasidone hydrochloride-inducedÂ alphaÂ blockade.Â In case of severe extrapyramidal symptoms, anticholinergic medication should be administered. Â  </paragraph>
                        <paragraph> Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered. Â  </paragraph>
                        <paragraph>The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DESCRIPTION">
               <id root="09b7b4b7-8333-dc36-2131-fca86b5b6ae8"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Lurasidone hydrochloride is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives.Â </paragraph>
                  <paragraph>Its chemical name is (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1- ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride. Its molecular formula is C<sub>28</sub>H<sub>36</sub>N<sub>4</sub>O<sub>2</sub>SÂ·HClÂ and its molecular weight is 529.14.Â </paragraph>
                  <paragraph>The chemical structure is:Â </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM186808563982"/>
                  </paragraph>
                  <paragraph>Lurasidone hydrochloride is a white to off-white powder. It is highly soluble in methanol, very slightly soluble in isopropyl alcohol and ethyl acetate, sparingly soluble in dimethylformamide and insoluble in toluene.Â </paragraph>
                  <paragraph>LurasidoneÂ hydrochloride tabletsÂ areÂ intendedÂ forÂ oralÂ administrationÂ only.Â EachÂ tabletÂ containsÂ 20Â mg,Â 40Â mg, 60 mg or 80 mgÂ of lurasidone hydrochloride.Â </paragraph>
                  <paragraph>InactiveÂ ingredientsÂ areÂ croscarmelloseÂ sodium, hypromellose, magnesiumÂ stearate, mannitol, microcrystalline cellulose, pregelatinized starch, polyethylene glycol and titanium dioxide. Â Additionally,Â theÂ 80Â mgÂ tabletÂ containsÂ iron oxide yellow and FD&amp;C Blue No. 2.</paragraph>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="CLINICAL_PHARMACOLOGY">
               <id root="1ca101ac-35e0-45c3-bc97-d653a6bbc8cc"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
               <component>
                  <section ID="_388a9100-53c5-8f30-56e3-d24eeaef6a45">
                     <id root="128dec89-53b5-99ec-f4bf-46e8d943f145"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>TheÂ mechanism ofÂ actionÂ ofÂ lurasidoneÂ inÂ theÂ treatmentÂ ofÂ bipolarÂ depression  is unclear. However, its efficacy in bipolar depression could be mediated throughÂ aÂ combinationÂ ofÂ centralÂ dopamineÂ D<sub>2</sub> andÂ serotoninÂ TypeÂ 2Â (5HT<sub>2A</sub>) receptor antagonism.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="PHARMACODYNAMICS">
                     <id root="7f8bf308-23ab-d8d8-e67a-909986f1fc0e"/>
                     <code code="43681-6" displayName="PHARMACODYNAMICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Lurasidone isÂ anÂ antagonistÂ withÂ highÂ affinity bindingÂ atÂ theÂ dopamineÂ D2 Â receptorsÂ (Ki of 1Â nM) and Â the Â serotonin Â 5-HT<sub>2A</sub> Â (Ki of 0.5 Â nM)Â Â and Â 5-HT7 (Ki of 0.5 Â nM) Â receptors. Â It Â also Â binds Â with Â moderate Â affinity Â to Â the Â human Â Î±<sub>2C</sub> Â adrenergic receptorsÂ (Ki of 11 nM), isÂ aÂ partialÂ agonistÂ atÂ serotonin 5-HT<sub>1A</sub> (Ki of 6.4Â nM)Â receptors,Â andÂ isÂ an antagonistÂ atÂ theÂ Î±<sub>2A</sub> adrenergicÂ receptorsÂ (Ki of 41Â nM). LurasidoneÂ exhibitsÂ littleÂ orÂ noÂ affinity for histamine H1Â and muscarinic M1Â receptors (IC<sub>50</sub>Â &gt; 1,000 nM).</paragraph>
                        <paragraph>
                           <content styleCode="italics">ECG Changes</content>
                        </paragraph>
                        <paragraph>The effects of lurasidone hydrochloride on the QTc interval were evaluated in a randomized, double-blind, multiple-dose, parallel-dedicated thorough QT study in 43 patients with another indication, who were treated with lurasidone hydrochloride doses of 120 mg daily, 600 mg daily and completed the study. The maximum mean (upper 1-sided, 95% CI) increase in baseline adjusted QTc intervals based on individual correction method (QTcI) was 7.5 (11.7) ms and 4.6 (9.5) ms, for the 120 mg and 600 mg dose groups respectively, observed at 2 to 4 hours after dosing. In this study, there was no apparent dose (exposure)-response relationship. Â  </paragraph>
                        <paragraph>In short-term, placebo-controlled studies in bipolar depression and another indication, no post-baseline QT prolongations exceeding 500 msec were reported in patients treated with lurasidone hydrochloride or placebo.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="PHARMACOKINETICS">
                     <id root="8481c5f7-28cb-c076-6501-3714a2be3ea8"/>
                     <code code="43682-4" displayName="PHARMACOKINETICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold italics">Adults</content>
                        </paragraph>
                        <paragraph>TheÂ activity ofÂ lurasidone hydrochlorideÂ isÂ primarilyÂ dueÂ toÂ theÂ parentÂ drug. The pharmacokineticsÂ of lurasidone hydrochloride isÂ dose-proportionalÂ withinÂ aÂ totalÂ dailyÂ doseÂ rangeÂ of 20Â mgÂ toÂ 160Â mg.Â Steady-state concentrations of lurasidone hydrochloride are reached within 7 days of starting lurasidone hydrochloride tablets.</paragraph>
                        <paragraph>FollowingÂ administrationÂ ofÂ 40Â mgÂ ofÂ lurasidone hydrochloride,Â theÂ meanÂ (%CV)Â eliminationÂ half-life wasÂ 18 (7) hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">AbsorptionÂ andÂ Distribution: </content>Lurasidone hydrochloride isÂ absorbed andÂ reachesÂ peakÂ serumÂ concentrationsÂ in approximately 1 to 3 hours. Â It Â is Â estimated Â that Â 9 to 19% Â of Â an Â administered Â dose Â is Â absorbed. Following administration of 40 mg of lurasidone hydrochloride, theÂ mean (%CV) apparent volume of distribution was 6,173 (17.2) L. Lurasidone hydrochloride is highly bound (~99%) to serum proteins.</paragraph>
                        <paragraph>InÂ aÂ foodÂ effectÂ study,Â lurasidoneÂ hydrochloride meanÂ C<sub>max</sub> and AUCÂ wereÂ aboutÂ 3-timesÂ andÂ 2-times, respectively,Â whenÂ administered with food compared to the levelsÂ observedÂ underÂ fasting conditions. Lurasidone hydrochloride exposure was not affected as meal size was increased from 350 to 1,000 calories and was independent of mealÂ fat contentÂ <content styleCode="italics">[see Dosage and Administration </content>(<content styleCode="bold">
                              <linkHtml href="#_b30d332c-3939-8af6-1706-567e2831f491">2.3</linkHtml>
                           </content>)<content styleCode="italics">].</content>Â </paragraph>
                        <paragraph>In clinical studies, establishing the safety and efficacy of lurasidone hydrochloride, patients were instructed to take their daily dose with food<content styleCode="italics">Â [see Dosage and Administration</content> (<content styleCode="bold">
                              <linkHtml href="#_b30d332c-3939-8af6-1706-567e2831f491">2.3</linkHtml>
                           </content>)<content styleCode="italics">].Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism andÂ Elimination:</content>Â Lurasidone hydrochlorideÂ isÂ metabolizedÂ mainlyÂ viaÂ CYP3A4.Â TheÂ major biotransformationÂ pathwaysÂ areÂ oxidative N-dealkylation,Â hydroxylationÂ ofÂ norbornaneÂ ring,Â and S-oxidation. Lurasidone hydrochloride isÂ metabolized into two active metabolites (ID-14283 and ID-14326) and two Â major Â non-active Â metabolites (ID-20219 Â and Â ID-20220). Â Based Â on Â <content styleCode="italics">in Â vitro</content> Â studies, lurasidone hydrochloride is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes. Because lurasidone hydrochloride is not a substrate for CYP1A2, smoking is not expected to have an effect on the pharmacokinetics of lurasidone hydrochloride.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Transporter proteins</content>:<content styleCode="italics"> In vitro</content> studies suggest lurasidone hydrochloride is not a substrate of OATP1B1 or OATP1B3, however, is probably a substrate of P-gp and BCRP. <content styleCode="italics">In vitro</content> studies indicate that lurasidone hydrochloride is not expected to inhibit transporters OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, MATE2-K and BSEP at clinically relevant concentrations. Lurasidone hydrochloride is not a clinically significant inhibitor of P-gp. However, it may inhibit BCRP.</paragraph>
                        <paragraph>Total excretion of radioactivity in urine and feces combined was approximately 89%, with about 80% recovered in feces and 9% recovered in urine, after a single dose of [<sup>14</sup>C]-labeled lurasidone hydrochloride.Â </paragraph>
                        <paragraph>FollowingÂ administrationÂ ofÂ 40Â mg ofÂ lurasidone hydrochloride,Â theÂ meanÂ (%CV)Â apparent clearanceÂ wasÂ 3,902 (18) mL/min.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>Effects of other drugs on the exposure of lurasidone are summarized in Figure 1. A population PK analyses concluded that coadministration of lithium 300 to 2,400 mg/day or valproate 300 to 2,000 mg/day with lurasidone for up to 6 weeks has minimal effect on lurasidone exposure. Â  </paragraph>
                        <paragraph>And the effects of lurasidone hydrochloride on the exposures of other drugs are summarized in Figure 2. A population PK analyses concluded that coadministration of lurasidone has minimal effect on lithium and valproate exposure when it is coadministered with lithium 300 to 2,400 mg/day or valproate 300 to 2,000 mg/day.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1: Impact of Other Drugs on </content>
                           <content styleCode="bold">Lurasidone Hydrochloride Pharmacokinetics</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM990045371314"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 2: Impact of </content>
                           <content styleCode="bold">Lurasidone Hydrochloride on Other Drugs</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM36275844619"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Studies in Specific Populations</content>
                        </paragraph>
                        <paragraph> The effect of intrinsic patient factors on the pharmacokinetics of lurasidone hydrochloride is presented in Figure 3. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>Lurasidone hydrochloride exposure (i.e., steady-state C<sub>max</sub> and AUC) in children and adolescent patients (10 to 17 years of age) was generally similar to that in adults across the dose range from 40 to 160 mg, without adjusting for body weight.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 3: Impact of Other Patient Factors on </content>
                           <content styleCode="bold">Lurasidone Hydrochloride Pharmacokinetics </content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM327435983319"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="NONCLINICAL_TOXICOLOGY">
               <id root="24a279f4-536c-a599-b01d-3723d7f4459c"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
               <component>
                  <section ID="CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">
                     <id root="93d60d9a-e1ed-d897-4f79-3876955018be"/>
                     <code code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Carcinogenesis:</content> Lurasidone increased incidences of malignant mammary gland tumors and pituitary gland adenomasÂ in female mice orally dosed with 30, 100, 300, or 650 mg/kg/day. The lowestÂ doseÂ producedÂ plasmaÂ levels (AUC) approximately equal to those in humans receiving the MRHD of 160 mg/day. No increases in tumors were seen in male mice up to the highest dose tested, which produced plasma levels (AUC) 14 times those in humans receiving the MRHD. Â </paragraph>
                        <paragraph>LurasidoneÂ increasedÂ theÂ incidenceÂ of mammaryÂ glandÂ carcinomas in female rats orally dosed at 12Â andÂ 36Â mg/kg/day: the lowest dose; 3Â mg/kg/dayÂ isÂ theÂ no-effect dose whichÂ producedÂ plasma levelsÂ (AUC)Â 0.4 timesÂ thoseÂ inÂ humansÂ receiving theÂ MRHD.Â NoÂ increases inÂ tumorsÂ wereÂ seen in male rats up to the highest dose tested, which produced plasma levels (AUC) 6 times those in humans receiving the MRHD.</paragraph>
                        <paragraph>
                           <content>Proliferative and/or neoplastic changes in the mammary and pituitary glands of rodents have been observed following chronic administration of antipsychotic drugs and are considered to be prolactin-mediated</content>Â <content styleCode="italics">[see Warnings and Precautions</content> (<content styleCode="bold">
                              <linkHtml href="#_bc1f52e9-67f4-8271-ff7e-e7cc04d8ec54">5.7</linkHtml>
                           </content>)<content styleCode="italics">].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Mutagenesis:Â </content>LurasidoneÂ didÂ notÂ causeÂ mutation orÂ chromosomalÂ aberrationÂ whenÂ tested <content styleCode="italics">in vitro</content> and <content styleCode="italics">inÂ vivo</content> test <content styleCode="italics">battery</content>. Lurasidone was negative in the Ames gene mutation test, the Chinese Hamster Lung (CHL) cells, and in the <content styleCode="italics">in vivo</content> mouse bone marrow micronucleus test upÂ toÂ 2,000Â mg/kg which is 61 times the MRHD of 160 mg/day based on mg/m<sup>2</sup>Â body surface area. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Impairment Â of Â Fertility:</content> Â Estrus Â cycle Â irregularities Â were Â seen Â in Â rats Â orally Â administered lurasidone atÂ 1.5,Â 15Â andÂ 150Â mg/kg/day forÂ 15Â consecutiveÂ daysÂ priorÂ toÂ mating,Â duringÂ the mating period, and through gestation day 7. No effect was seen at the lowest dose of 0.1 mg/kg which is approximately 0.006 times the MRHD of 160 mg/day based on mg/m<sup>2</sup>. Fertility was reduced only at the highest dose, which was reversible after a 14 day drug-free period. The no-effect dose for reduced fertility was approximately equal to the MRHD based on mg/m<sup>2</sup>.Â </paragraph>
                        <paragraph>Lurasidone had no effect on fertility in male rats treated orally for 64 consecutive days prior to mating and during the mating period at doses up to 9 times the MRHD based on mg/m<sup>2</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="CLINICAL_STUDIES">
               <id root="a4e916c3-abf3-5a8a-9c7d-736ee2957a57"/>
               <code code="34092-7" displayName="CLINICAL STUDIES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
               <component>
                  <section ID="_d711956a-c8d2-2fb5-6914-2fc9cce2952e">
                     <id root="f6722357-5466-9b47-d292-fcb221a670d9"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.2 Depressive Episodes Associated with Bipolar I Disorder</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold italics">Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Monotherapy</content>
                        </paragraph>
                        <paragraph>The efficacy of lurasidone hydrochloride, as monotherapy, was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of adult patients (mean age of 41.5 years, range 18 to 74) who met DSM-IV-TR criteria for major depressive episodes associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=485). Patients were randomized to oneÂ ofÂ twoÂ flexible-doseÂ rangesÂ ofÂ lurasidone hydrochloride (20Â toÂ 60Â mg/day,Â or 80 to 120 mg/day) or placebo.</paragraph>
                        <paragraph>The primary rating instrument used to assess depressive symptoms in this study was the Montgomery-Asberg Depression Rating Scale (MADRS),Â aÂ 10-item clinician-ratedÂ scaleÂ with total Â scores Â ranging Â fromÂ 0 Â (no Â depressive Â features) Â to Â 60 Â (maximum Â score). Â The primary endpointÂ wasÂ theÂ changeÂ from baselineÂ in MADRSÂ scoreÂ atÂ WeekÂ 6.Â TheÂ keyÂ secondary instrument was the Clinical Global Impression-Bipolar-Severity of Illness scale (CGI-BP-S), a clinician-ratedÂ scaleÂ thatÂ measuresÂ theÂ subjectâs currentÂ illnessÂ stateÂ onÂ aÂ 7-pointÂ scale,Â whereÂ a higher score is associated with greater illness severity.</paragraph>
                        <paragraph>ForÂ bothÂ doseÂ groups,Â lurasidoneÂ hydrochloride wasÂ superiorÂ to placeboÂ inÂ reductionÂ ofÂ MADRSÂ andÂ CGI-BP-S scores atWeek 6. The primaryÂ efficacyÂ results areÂ providedÂ inÂ Table 37.Â TheÂ highÂ doseÂ rangeÂ (80 toÂ 120Â mgÂ perÂ day)Â did not provide additional efficacy on average,Â comparedÂ toÂ theÂ lowÂ dose range (20 to 60 mg per day).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adjunctive Therapy with Lithium or Valproate</content>
                        </paragraph>
                        <paragraph>TheÂ efficacyÂ ofÂ lurasidone hydrochloride,Â asÂ anÂ adjunctive therapyÂ withÂ lithiumÂ orÂ valproate,Â wasÂ establishedÂ in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of adult patients (meanÂ ageÂ ofÂ 41.7Â years,Â rangeÂ 18Â toÂ 72)Â who metÂ DSM-IV-TR criteriaÂ forÂ majorÂ depressive episodes associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=340).Â PatientsÂ whoÂ remainedÂ symptomaticÂ afterÂ treatmentÂ withÂ lithium or valproate were randomized to flexibly dosed lurasidone hydrochloride 20 to 120 mg/day or placebo. Â  </paragraph>
                        <paragraph>The primary rating instrument used to assess depressive symptoms in this study was the MADRS. The primary endpoint was the changeÂ from baselineÂ inÂ MADRSÂ scoreÂ atÂ WeekÂ 6.Â The key secondary instrument was the CGI-BP-S scale. Â  </paragraph>
                        <paragraph>Lurasidone hydrochloride was superior to placebo in reduction of MADRS and CGI-BP-S scores at Week 6, as an adjunctive therapy with lithiumÂ or valproate (Table 37).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 37: Primary Efficacy Results for Adult Studies in Depressive Episodes Associated with Bipolar I Disorder (MADRS Scores)</content>
                        </paragraph>
                        <table border="1" cellpadding="3" width="85%">
                           <tbody align="center">
                              <tr>
                                 <td>Â </td>
                                 <td>Â </td>
                                 <td>
                                    <content styleCode="bold">PrimaryÂ EfficacyÂ Measure:Â MADRS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Study</content>Â </td>
                                 <td>
                                    <content styleCode="bold">TreatmentÂ Group</content>Â </td>
                                 <td>
                                    <content styleCode="bold">Mean Baseline Score<br/>(SD)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">LS Mean Change fromÂ BaselineÂ <br/>(SE)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo-subtracted Difference<sup>a</sup>Â (95%Â CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Monotherapy studyÂ </td>
                                 <td>Lurasidone hydrochloride <br/>(20 to 60 mg/day)*</td>
                                 <td>30.3Â (5.0)Â </td>
                                 <td>-15.4Â (0.8)Â </td>
                                 <td>-4.6Â (-6.9,Â -2.3)Â </td>
                              </tr>
                              <tr>
                                 <td>Â </td>
                                 <td>LurasidoneÂ  hydrochloride <br/>(80 to 120Â mg/day)*</td>
                                 <td>30.6Â (4.9)Â </td>
                                 <td>-15.4Â (0.8)Â </td>
                                 <td>-4.6Â (-6.9,Â -2.3)Â </td>
                              </tr>
                              <tr>
                                 <td>Â </td>
                                 <td>Placebo</td>
                                 <td>30.5Â (5.0)</td>
                                 <td>-10.7Â (0.8)</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>Adjunctive TherapyÂ studyÂ </td>
                                 <td>LurasidoneÂ  hydrochloride <br/>(20 to 120Â mg/day)*Â + lithium orÂ valproateÂ </td>
                                 <td>30.6Â (5.3)</td>
                                 <td>-17.1Â (0.9)</td>
                                 <td>-3.6Â (-6.0,Â -1.1)Â </td>
                              </tr>
                              <tr>
                                 <td>Â </td>
                                 <td>PlaceboÂ +Â lithium orÂ valproate</td>
                                 <td>30.8Â (4.8)</td>
                                 <td>-13.5Â (0.9)</td>
                                 <td>-</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>SD:Â standardÂ deviation;Â SE:Â standardÂ error; LSÂ Mean: least-squaresÂ mean;Â CI: confidenceÂ interval,Â unadjustedÂ forÂ multiple comparisons.</paragraph>
                        <paragraph>
                           <sup>a</sup>Â DifferenceÂ (drugÂ minusÂ placebo)Â inÂ least-squaresÂ meanÂ changeÂ fromÂ baseline.Â </paragraph>
                        <paragraph>*Â TreatmentÂ groupÂ statisticallyÂ significantlyÂ superior toÂ placebo.</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <paragraph>The efficacy of lurasidone hydrochloride was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of pediatric patients (10 to 17 years) who met DSM-5 criteria for a major depressive episode associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=343). Patients were randomized to flexibly dosed lurasidone hydrochloride 20 to 80 mg/day or placebo. At the end of the clinical study, most patients (67%) received 20 mg/day or 40 mg/day. </paragraph>
                        <paragraph>The primary rating scale used to assess depressive symptoms in this study was the Childrenâs Depression Rating Scale, Revised (CDRS-R) total score. The CDRSâR is a 17-item clinician-rated scale with total scores ranging from 17 to 113. The primary endpoint was the change from baseline in CDRS-R score at Week 6. The key secondary endpoint was the change from baseline in CGI-BP-S depression score. </paragraph>
                        <paragraph>Lurasidone hydrochloride was superior to placebo in reduction of CDRS-R total score and CGIâBP-S depression score at Week 6. The primary efficacy results are provided in Table 38. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 38</content>
                           <content styleCode="bold">:</content>
                           <content styleCode="bold"> Primary Efficacy Results for the Study in Depressive Episodes Associated with Bipolar I Disorder (CDRS-R Total Score) in Pediatric Patients (10 to 17 years)</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td align="left" rowspan="2">
                                    <content styleCode="bold">Treatment Group</content>
                                 </td>
                                 <td align="center" colspan="3">
                                    <content styleCode="bold">Primary Efficacy Measure: CDRS-R</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Mean Baseline</content>
                                    <content styleCode="bold">Score (SD)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">LS Mean Change</content>
                                    <content styleCode="bold">from Baseline</content>
                                    <content styleCode="bold">(SE)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo-subtracted</content>
                                    <content styleCode="bold">Difference<sup>a</sup> (95%</content>
                                    <content styleCode="bold">CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">Lurasidone hydrochloride (20 to 80 mg/day)*</td>
                                 <td>59.2 (8.24)</td>
                                 <td>-21.0 (1.06)</td>
                                 <td>-5.7 (-8.4, -3.0)</td>
                              </tr>
                              <tr>
                                 <td align="left">Placebo</td>
                                 <td>58.6 (8.26)</td>
                                 <td>-15.3 (1.08)</td>
                                 <td>--</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple comparisons.<sup/>
                        </paragraph>
                        <paragraph>
                           <sup>a </sup>Difference (drug minus placebo) in least-squares mean change from baseline.</paragraph>
                        <paragraph>* Treatment group statistically significantly superior to<content styleCode="bold"/>placebo.<content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="HOW_SUPPLIED">
               <id root="876a4167-c5b6-0e68-2630-f6366b54fe7e"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Lurasidone hydrochloride tablets are available in the following strengths and package configurations. Â </paragraph>
                  <paragraph>20 mg tablets are white to off white, round shaped, film-coated tablets debossed with â351â on one side, â20â on other side and free from physical defects, and are supplied in bottles of 30, 90, 500 and unit dose packages of 100 (10 x 10).Â </paragraph>
                  <paragraph>Bottles of 30 NDC 43598-351-30</paragraph>
                  <paragraph>Bottles of 90 NDC 43598-351-90 </paragraph>
                  <paragraph>Bottles of 500 NDC 43598-351-05</paragraph>
                  <paragraph>Unit dose packages of 100 (10 x 10) NDC 43598-351-78Â </paragraph>
                  <paragraph>40 mg tablets are white to off white, round shaped, film-coated tablets debossed with â352â on one side, â40â on other side and free from physical defects, and are supplied in bottles of 30, 90, 500 and unit dose packages of 100 (10 x 10).Â </paragraph>
                  <paragraph>Bottles of 30 NDC 43598-352-30</paragraph>
                  <paragraph>Bottles of 90 NDC 43598-352-90</paragraph>
                  <paragraph>Bottles of 500 NDC 43598-352-05</paragraph>
                  <paragraph>Unit dose packages of 100 (10 x 10) NDC 43598-352-78</paragraph>
                  <paragraph>60 mg tablets are white to off white, capsule shaped, film-coated tablets debossed with â353â on one side, â60â on other side and free from physical defects, and are supplied in bottles of 30, 90, 500 and unit dose packages of 100 (10 x 10).Â </paragraph>
                  <paragraph>Bottles of 30 NDC 43598-353-30</paragraph>
                  <paragraph>Bottles of 90 NDC 43598-353-90</paragraph>
                  <paragraph>Bottles of 500 NDC 43598-353-05</paragraph>
                  <paragraph>Unit dose packages of 100 (10 x 10) NDC 43598-353-78Â </paragraph>
                  <paragraph>80 mg tablets are pale green, oval shaped, film-coated tablets debossed with â354â on one side, â80â on other side and free from physical defects, and are supplied in bottles of 30, 90, 500 and unit dose packages of 100 (10 x 10).Â  </paragraph>
                  <paragraph>Bottles of 30 NDC 43598-354-30</paragraph>
                  <paragraph>Bottles of 90 NDC 43598-354-90</paragraph>
                  <paragraph>Bottles of 500 NDC 43598-354-05</paragraph>
                  <paragraph>Unit dose packages of 100 (10 x 10) NDC 43598-354-78Â </paragraph>
                  <paragraph>
                     <content styleCode="italics underline">Storage</content>
                  </paragraph>
                  <paragraph>StoreÂ lurasidoneÂ hydrochloride tabletsÂ atÂ 20Â°C to 25Â°C (68Â°F to 77Â°F) [See USP Controlled Room Temperature].Â </paragraph>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="INFORMATION_FOR_PATIENTS">
               <id root="6869d4c2-7db4-b7bb-ee61-f20607b20d26"/>
               <code code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide). Â  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Suicidal Thoughts and Behavior</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down and instruct them to report such symptoms to the healthcare provider <content styleCode="italics">[see </content>
                     <linkHtml href="#BOXED_WARNING">Boxed Warning</linkHtml>
                     <content styleCode="italics">, Warnings and Precautions (</content>
                     <linkHtml href="#_f4c6c181-4e79-9e4b-fac8-30b76b163a6c">5.2)</linkHtml>
                     <content styleCode="italics">].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"> Neuroleptic Malignant Syndrome</content>
                  </paragraph>
                  <paragraph>Counsel patients about a potentially fatal adverse reaction referred to as Neuroleptic Malignant Syndrome (NMS). Advise patients, family members, or caregivers to contact the healthcare provider or to report to the emergency room if they experience signs and symptoms of NMS <content styleCode="italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_2597bb6f-80c9-5f91-5c55-9068d1acbf85">5.4</linkHtml>
                     <content styleCode="italics">)]</content>. Â  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Tardive Dyskinesia</content>
                  </paragraph>
                  <paragraph>Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur <content styleCode="italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_cf40cc08-2a0c-7eca-6b2f-5883e42f251e">5.5</linkHtml>
                     <content styleCode="italics">)].</content> Â  </paragraph>
                  <paragraph>
                     <content styleCode="underline"> Metabolic Changes</content>
                  </paragraph>
                  <paragraph>Educate patients about the risk of metabolic changes, how to recognize symptoms of hyperglycemia and diabetes mellitus, and the need for specific monitoring, including blood glucose, lipids, and weight <content styleCode="italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_728ef4cc-2114-48f5-157f-2cd238c2da9e">5.6</linkHtml>
                     <content styleCode="italics">)]. Â  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"> Hyperprolactinemia</content>
                  </paragraph>
                  <paragraph> Counsel patients on signs and symptoms of hyperprolactinemia that may be associated with chronic use of lurasidone hydrochloride tablets. Advise them to seek medical attention if they experience any of the following: amenorrhea or galactorrhea in females, erectile dysfunction or gynecomastia in males <content styleCode="italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_bc1f52e9-67f4-8271-ff7e-e7cc04d8ec54">5.7</linkHtml>
                     <content styleCode="italics">)]. Â  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Leukopenia/Neutropenia</content>
                  </paragraph>
                  <paragraph> Advise Â patients Â with Â a Â pre-existing Â low Â WBC Â or Â a Â history Â of drug-induced leukopenia/neutropenia that they should have their CBC monitored while taking lurasidone hydrochloride tabletsÂ <content styleCode="italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_3bcfe14b-6741-4ff0-3487-cf641edd449a">5.8</linkHtml>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"> Orthostatic Hypotension</content>
                  </paragraph>
                  <paragraph> Educate patients about the risk of orthostatic hypotension, particularly at the time of initiating treatment, re-initiating treatment, or increasing the dose <content styleCode="italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_e2e5a0af-303a-3a0d-9210-0cfc2550de00">5.9</linkHtml>
                     <content styleCode="italics">)]. Â  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics"/>
                     <content styleCode="underline">InterferenceÂ withÂ CognitiveÂ andÂ MotorÂ Performance</content>
                  </paragraph>
                  <paragraph>Caution patients about performing activities requiring mental alertness, such as operating hazardousÂ machineryÂ orÂ operatingÂ aÂ motorÂ vehicle,Â untilÂ theyÂ areÂ reasonably certain that lurasidone hydrochloride therapy does not affect themÂ adversely <content styleCode="italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_004a8873-7786-af88-121a-a17410c55cf9">5.12</linkHtml>
                     <content styleCode="italics">)].</content> Â  </paragraph>
                  <paragraph>
                     <content styleCode="underline">HeatÂ ExposureÂ andÂ Dehydration</content>
                  </paragraph>
                  <paragraph> Educate patients regarding appropriate care in avoiding overheating and dehydration <content styleCode="italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_ed5bc472-3d28-0d5f-88ab-6532514c9729">5.13</linkHtml>
                     <content styleCode="italics">)]. Â </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Activation of Mania or Hypomania</content>
                  </paragraph>
                  <paragraph> Advise patients and their caregivers to observe for signs of activation of mania/hypomania <content styleCode="italics">[see Warnings and Precautions (</content>
                     <linkHtml href="#_e9d908ad-c3e6-0fbc-323f-7b135f288087">5.14</linkHtml>
                     <content styleCode="italics">)]. Â  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Concomitant MedicationÂ </content>
                  </paragraph>
                  <paragraph> AdviseÂ patientsÂ toÂ informÂ theirÂ physicians ifÂ they areÂ taking,Â orÂ planÂ toÂ take,Â anyÂ prescriptionÂ or over-the-counterÂ drugs, becauseÂ thereÂ isÂ aÂ potentialÂ forÂ drugÂ interactionsÂ [<content styleCode="italics">see Drug Interactions ( <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml> )</content>]. Â  </paragraph>
                  <paragraph>
                     <content styleCode="underline"> Pregnancy</content>
                  </paragraph>
                  <paragraph>Advise patients that lurasidone hydrochloride tablets may cause extrapyramidal and/or withdrawal symptoms in a neonate. Advise patients to notify their healthcare provider with a known or suspected pregnancy<content styleCode="italics"> [see Use in Specific Populations (</content>
                     <linkHtml href="#PREGNANCY">8.1</linkHtml>
                     <content styleCode="italics">)]. </content> Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lurasidoneÂ hydrochloride during pregnancy [<content styleCode="italics">see Use in Specific Populations (<linkHtml href="#PREGNANCY">8.1</linkHtml>)</content>].</paragraph>
                  <paragraph>Rx only Â  </paragraph>
                  <paragraph>Distributor: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dr. Reddyâs Laboratories Inc.,</content>
                  </paragraph>
                  <paragraph> Princeton, NJ 08540</paragraph>
                  <paragraph>
                     <content styleCode="bold">Made in India</content>
                  </paragraph>
                  <paragraph>Revised: 02/2025</paragraph>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="_b42df579-d79f-ab76-8bed-4180e6ec7e40">
               <id root="fce84a6d-f2f5-d0ca-9512-8eb996af2063"/>
               <code code="42231-1" displayName="SPL MEDGUIDE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <table border="1" frame="box" rules="all">
                     <tbody>
                        <tr>
                           <td align="center">
                              <content styleCode="bold">MEDICATION GUIDE</content>
                              <content styleCode="bold">
                                 <br/>Lurasidone </content>
                              <content styleCode="bold">Hydrochloride</content>Â <content styleCode="bold">(loo rasâ i done hyeâ droe klorâ ide) <br/>
                              </content>
                              <content styleCode="bold">Tablets</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">What is the most important information I should know about lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets</content>
                              <content styleCode="bold">?</content>
                              <content styleCode="bold">
                                 <br/>Lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets</content>
                              <content styleCode="bold"> may cause serious side effects, including:</content>
                              <content styleCode="bold">
                                 <br/>
                                 <br/>â¢ Increased risk of death in elderly people with dementia-related psychosis. </content>Medicines like lurasidoneÂ hydrochloridetablets can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). Lurasidone hydrochloride tablets are not approved for the treatment of people with dementia-related psychosis. <content styleCode="bold">
                                 <br/>
                                 <br/>â¢ Increased risk of suicidal thoughts or actions in children and young adults.</content> Antidepressant medicines may increase suicidal thoughts or actions in some children and young adults within the first few months of treatment and when the dose is changed. <br/>
                              <content styleCode="bold">â¢ </content>
                              <content styleCode="bold">Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. </content>These include people who have (or have a family history of) depression, bipolar illness (also called manic-depressive illness), or a history of suicidal thoughts or actions. <content styleCode="bold">
                                 <br/>
                                 <br/>How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member? </content>
                              <br/>
                              <content styleCode="bold">â¢ </content>Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.<br/>
                              <content styleCode="bold">â¢ </content>Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. <br/>
                              <content styleCode="bold">â¢ </content>Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms. <content styleCode="bold">
                                 <br/>Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:</content>
                              <br/>
                              <content styleCode="bold">â¢ </content>thoughts about suicide or dying <br/>
                              <content styleCode="bold">â¢ </content>attempts to commit suicide <br/>
                              <content styleCode="bold">â¢ </content>new or worse depression <br/>
                              <content styleCode="bold">â¢ </content>new or worse anxiety <br/>
                              <content styleCode="bold">â¢ </content>feeling very agitated or restless <br/>
                              <content styleCode="bold">â¢ </content>panic attacks <br/>
                              <content styleCode="bold">â¢ </content>trouble sleeping (insomnia) <br/>
                              <content styleCode="bold">â¢ </content>new or worse irritability <br/>
                              <content styleCode="bold">â¢ </content>acting aggressive, being angry, or violent <br/>
                              <content styleCode="bold">â¢ </content>acting on dangerous impulses <br/>
                              <content styleCode="bold">â¢ </content>an extreme increase in activity and talking (mania) <br/>
                              <content styleCode="bold">â¢ </content>other unusual changes in behavior or mood </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <br/>What is lurasidone </content>
                              <content styleCode="bold">hydrochloride?</content>
                              <br/>Lurasidone hydrochloride is a prescription medicine used: <br/>
                              <br/>
                              <content styleCode="bold">â¢ </content>Alone to treat people 10 years of age and older with depressive episodes that happen with Bipolar I Disorder (bipolar depression). <br/>
                              <content styleCode="bold">â¢ </content>With the medicine lithium or valproate to treat adults with depressive episodes that happen with Bipolar I Disorder (bipolar depression). <br/>
                              <br/>It is not known if lurasidone hydrochloride tablets are safe and effective in children:<br/>
                              <content styleCode="bold">â¢ </content>less than 10 years of age with bipolar depression. <br/>
                              <content styleCode="bold">â¢ </content>for the treatment of irritability associated with autistic disorder. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <br/>Do not take lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets if you are:</content>
                              <br/>
                              <content styleCode="bold">â¢ </content>allergic to lurasidone hydrochloride or any of the ingredients in lurasidone hydrochloride tablets. See the end of this Medication Guide for a complete list of ingredients in lurasidone hydrochloride tablets. <br/>
                              <content styleCode="bold">â¢ </content>taking certain other medicines called CYP3A4 inhibitors or inducers including ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, rifampin, avasimibe, St. Johnâs wort, phenytoin, or carbamazepine. Ask your healthcare provider if you are not sure if you are taking any of these medicines. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <br/>Before taking lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets, tell your healthcare provider </content>
                              <content styleCode="bold">about all of your medical conditions, including if you:</content>
                              <br/>
                              <content styleCode="bold">â¢ </content>have or have had heart problems or stroke <br/>
                              <content styleCode="bold">â¢ </content>have or have had low or high blood pressure <br/>
                              <content styleCode="bold">â¢ </content>have or have had diabetes or high blood sugar, or have a family history of diabetes or high blood sugar.Â <br/>
                              <content styleCode="bold">â¢ </content>have or have had high levels of total cholesterol or triglyceridesÂ <br/>
                              <content styleCode="bold">â¢ </content>have or have had high prolactin levels <br/>
                              <content styleCode="bold">â¢ </content>have or have had low white blood cell count <br/>
                              <content styleCode="bold">â¢ </content>have or have had seizures <br/>
                              <content styleCode="bold">â¢ </content>have or have had kidney or liver problemsÂ <br/>
                              <content styleCode="bold">â¢ </content>are pregnant or plan to become pregnant. It is not known if lurasidone hydrochloride will harm your unborn baby. Talk to your healthcare provider about the risk to your unborn baby if you take lurasidone hydrochloride tablets during pregnancy. <br/>
                              <content styleCode="bold">â¢ </content>Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with lurasidone hydrochloride tablets. <br/>
                              <content styleCode="bold">â¢ </content>If you become pregnant during treatment with lurasidone hydrochloride tablets, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or go to http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/. <br/>
                              <content styleCode="bold">â¢ </content>are breastfeeding or plan to breastfeed. It is not known if lurasidone hydrochloride passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with lurasidone hydrochloride tablets. <content styleCode="bold">
                                 <br/>
                                 <br/>Tell your healthcare provider about all the medicines you take,</content>Â including prescription and over-the-counter medicines, vitamins, and herbal supplements. <br/>
                              <br/>Lurasidone hydrochloride tablets and other medicines may affect each other causing possible serious side effects. Lurasidone hydrochloride tablets may affect the way other medicines work, and other medicines may affect how lurasidone hydrochloride tablets work. <br/>
                              <br/>Your healthcare provider can tell you if it is safe to takeÂ lurasidone hydrochloride tablets with your other medicines. Do not start or stop any other medicines during treatment with lurasidone hydrochloride tablets without talking to your healthcare provider first. <br/>
                              <br/>Know the medicines you take. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <br/>How should I take lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets?</content>
                              <br/>
                              <content styleCode="bold">â¢ </content>Take lurasidone hydrochloride tablets exactly as your healthcare provider tells you to take it. Do not change the dose or stop taking lurasidone hydrochloride tablets without first talking to your healthcare provider. <br/>
                              <content styleCode="bold">â¢ </content>Take lurasidone hydrochlorideÂ tablets by mouth, with food (at least 350 calories). <br/>
                              <content styleCode="bold">â¢ </content>If you take too much lurasidone hydrochlorideÂ tablets, call your healthcare provider or poison control center or go to the nearest hospital emergency room right away. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <br/>What should I avoid while taking lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets?</content>
                              <br/>
                              <content styleCode="bold">â¢ </content>Do not drive, operate heavy machinery, or do other dangerous activities until you know how lurasidone hydrochloride tablets affects you. Lurasidone hydrochloride tablets may make you drowsy. <br/>
                              <content styleCode="bold">â¢ </content>Avoid eating grapefruit or drinking grapefruit juice during treatment with lurasidone hydrochloride tablets. Grapefruit and grapefruit juice may affect the amount of lurasidone hydrochlorideÂ in your blood. <br/>
                              <content styleCode="bold">â¢ </content>Do not become too hot or dehydrated during treatment with lurasidone hydrochlorideÂ tablets.<br/>
                              <content styleCode="bold">â¢ </content>Do not exercise too much. <br/>
                              <content styleCode="bold">â¢ </content>In hot weather, stay inside in a cool place if possible. <br/>
                              <content styleCode="bold">â¢ </content>Stay out of the sun. <br/>
                              <content styleCode="bold">â¢ </content>Do not wear too much clothing or heavy clothing. <br/>
                              <content styleCode="bold">â¢ </content>Drink plenty of water. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <br/>What are the possible side effects of lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets?</content>
                              <br/>
                              <content styleCode="bold">Lurasidone hydrochloride tablets may cause serious side effects, including:</content>
                              <content styleCode="bold">
                                 <br/>â¢ See âWhat is the most important information I should know about lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets?â</content>
                              <content styleCode="bold">
                                 <br/>â¢ Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death. </content>
                              <content styleCode="bold">
                                 <br/>â¢ Neuroleptic malignant syndrome (NMS) a serious condition that can lead to death</content>. Call your healthcare provider or go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of NMS: <br/>
                              <content styleCode="bold">â¢ </content>high fever <br/>
                              <content styleCode="bold">â¢ </content>stiff muscles <br/>
                              <content styleCode="bold">â¢ </content>confusion <br/>
                              <content styleCode="bold">â¢</content>increased sweating <br/>
                              <content styleCode="bold">â¢ </content>changes in your breathing, heart rate, and blood pressure <content styleCode="bold">
                                 <br/>
                                 <br/>Uncontrolled body movements (tardive dyskinesia).</content> Lurasidone hydrochlorideÂ may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking lurasidone hydrochloride tablets. Tardive dyskinesia may also start after you stop taking lurasidone hydrochlorideÂ tablets. <content styleCode="bold">
                                 <br/>
                                 <br/>Problems with your metabolism such as:</content>
                              <content styleCode="bold">
                                 <br/>â¢ high blood sugar (hyperglycemia) and diabetes. </content>Increases in blood sugar can happen in some people who take lurasidone hydrochloride tablets. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes (such as being overweight or a family history of diabetes), your healthcare provider should check your blood sugar before you start and during treatment with lurasidone hydrochloride tablets. <content styleCode="bold">
                                 <br/>â¢ Call your healthcare provider </content>
                              <content styleCode="bold">if you have any of these symptoms of high blood sugar during treatment with lurasidone hydrochloride</content>
                              <content styleCode="bold"> tablets</content>
                              <content styleCode="bold">:</content>
                              <br/>
                              <content styleCode="bold">â¢ </content>feel very thirsty <br/>
                              <content styleCode="bold">â¢ </content>need to urinate more than usual <br/>
                              <content styleCode="bold">â¢ </content>feel very hungry <br/>
                              <content styleCode="bold">â¢ </content>feel weak or tired <br/>
                              <content styleCode="bold">â¢ </content>feel sick to your stomach <br/>
                              <content styleCode="bold">â¢ </content>feel confused, or your breath smells fruity <content styleCode="bold">
                                 <br/>
                                 <br/>increased fat levels (cholesterol and triglycerides) in your blood. </content>
                              <content styleCode="bold">
                                 <br/>
                                 <br/>weight gain. </content>You and your healthcare provider should check your weight regularly during treatment with lurasidone hydrochloride tablets. <content styleCode="bold">
                                 <br/>
                                 <br/>Increased prolactin levels in your blood (hyperprolactinemia). </content>Your healthcare provider may do blood tests to check your prolactin levels during treatment with lurasidone hydrochloride tablets. Tell your healthcare provider if you have any of the following signs and symptoms of hyperprolactinemia: <content styleCode="bold">
                                 <br/>
                                 <br/>Females: </content>
                              <br/>
                              <content styleCode="bold">â¢ </content>absence of your menstrual cycle <br/>
                              <content styleCode="bold">â¢ </content>secretion of breast milk when you are not breastfeeding <content styleCode="bold">
                                 <br/>
                                 <br/>Males: </content>
                              <br/>
                              <content styleCode="bold">â¢</content> problems getting or maintaining an erection (erectile dysfunction) <br/>
                              <content styleCode="bold">â¢ </content>enlargement of breasts (gynecomastia) <content styleCode="bold">
                                 <br/>
                                 <br/>Low white blood cell count. </content>Your healthcare provider may do blood tests during the first few months of treatment with lurasidone hydrochloride tablets. <content styleCode="bold">
                                 <br/>
                                 <br/>Decreased blood pressure (orthostatic hypotension). </content>You may feel lightheaded or faint when you rise too quickly from a sitting or lying position. <content styleCode="bold">
                                 <br/>
                                 <br/>Falls. </content>Lurasidone hydrochloride tablets may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries. <content styleCode="bold">
                                 <br/>
                                 <br/>Seizures (convulsions) </content>
                              <content styleCode="bold">
                                 <br/>
                                 <br/>â¢ Problems controlling your body temperature so that you feel too warm. </content>See âWhat should I avoid while taking lurasidone hydrochloride tablets?â <content styleCode="bold">
                                 <br/>
                                 <br/>â¢ Mania or hypomania </content>(manic episodes) in people with a history of bipolar disorder. <br/>Symptoms may include: <br/>
                              <content styleCode="bold">â¢ </content>greatly increased energy <br/>
                              <content styleCode="bold">â¢ </content>severe problems sleeping <br/>
                              <content styleCode="bold">â¢ </content>racing thoughts <br/>
                              <content styleCode="bold">â¢ </content>reckless behavior <br/>
                              <content styleCode="bold">â¢ </content>unusually grand ideas <br/>
                              <content styleCode="bold">â¢ </content>excessive happiness or irritability <br/>
                              <content styleCode="bold">â¢ </content>talking more or faster than usual <content styleCode="bold">
                                 <br/>
                                 <br/>Difficulty swallowing </content>
                              <content styleCode="bold">
                                 <br/>
                                 <br/>The most common side effects of lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets</content>
                              <content styleCode="bold"> include:</content>
                              <content styleCode="bold">
                                 <br/>
                                 <br/>â¢ Adults with bipolar depression: <br/>â¢ </content>restlessness and feeling like you need to move around (akathisia) <br/>
                              <content styleCode="bold">â¢ </content>difficulty moving, slow movements, muscle stiffness, or tremor <br/>
                              <content styleCode="bold">â¢ </content>sleepiness or drowsiness <br/>
                              <content styleCode="bold">
                                 <br/>â¢ Children 10 to 17 years of age with bipolar depression:</content>
                              <br/>
                              <content styleCode="bold">â¢</content> nausea <br/>
                              <content styleCode="bold">â¢</content> weight gain <br/>
                              <content styleCode="bold">â¢</content> problems sleeping (insomnia)<br/>
                              <br/>These are not all of the possible side effects of lurasidone hydrochloridetablets. <br/>
                              <br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <br/>How should I store lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets?</content>
                              <br/>
                              <content styleCode="bold">â¢ </content>Store lurasidone hydrochloride tablets at 20Â°C to 25Â°C (68Â°F to 77Â°F). <br/>
                              <content styleCode="bold">â¢ </content>Keep lurasidone hydrochloride tablets and all medicines out of the reach of children. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <br/>General information about the safe and effective use of lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets.</content>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use lurasidone hydrochloride tablets for a condition for which it was not prescribed. Do not give lurasidone hydrochlorideÂ tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about lurasidone hydrochloride tablets that is written for health professionals. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <br/>What are the ingredients in lurasidone </content>
                              <content styleCode="bold">hydrochloride</content>
                              <content styleCode="bold"> tablets?</content>
                              <content styleCode="bold">
                                 <br/>Active ingredient: </content>lurasidone hydrochloride <br/>
                              <content styleCode="bold">Inactive ingredients: </content>croscarmellosesodium, hypromellose, magnesiumÂ stearate, mannitol, microcrystalline cellulose, pregelatinized starch, polyethylene glycol and titanium dioxide. Additionally,Â theÂ 80Â mgÂ tablet containsÂ iron oxide yellow and FD&amp;C Blue No. 2. <br/>
                              <br/>For more information, call 1-888-375-3784.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.Â </paragraph>
                  <paragraph>To reorder additional Medication Guides contact Dr. Reddyâs Customer Service at 1-866-733-3952.Â </paragraph>
                  <paragraph> Rx only</paragraph>
                  <paragraph>Distributor: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dr. Reddyâs Laboratories Inc.,</content>
                  </paragraph>
                  <paragraph>Princeton, NJ 08540 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Made in India</content>
                  </paragraph>
                  <paragraph>Revised: 02/2025</paragraph>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="_4824a4b1-c977-2e39-c5fa-c36896fdf2ca">
               <id root="549d77f2-9179-6554-917d-4a410c25a22a"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION</title>
               <text>
                  <paragraph>20 mg : 30's count Container Label</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM422040808245"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="_aa75a79c-62ca-57f9-c04a-2b523e96a887">
               <id root="2f543971-26f9-9a8d-c2ae-57b8f214d60c"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>40 mg : 30's count Container Label</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM990570970631"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="_6a15d4ba-af79-53a3-cd44-4abab4836c51">
               <id root="2a4c3d47-a664-6e8c-93ba-e8a94c413823"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>60 mg : 30's count Container Label</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM268515872403"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="_de32e2ff-b630-1680-c3d0-c167fef2eb76">
               <id root="bce0b56d-c7ec-0273-e095-72e151a14ed8"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>80 mg : 30's count Container Label</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM595495744452"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="_36ed1bfb-e156-9caa-609f-db2fb2846a4d">
               <id root="de65db64-7154-4d0d-131c-54202be10b6e"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>20 mg : 100's count Carton Label</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM17033132784"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="_7527b8dd-f471-112e-dc6c-09417f8dc63a">
               <id root="b4ffc16a-dc1c-0925-9092-b83d56335efc"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>40 mg : 100's count Carton Label</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM309613880024"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="_44745f3e-19de-9b1b-3589-79b172a35a2b">
               <id root="38785f5f-eb03-25b7-e929-0f9ea4a5e960"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>60 mg : 100's count Carton Label</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM168384972006"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
         <component>
            <section ID="_eb73d3a3-cc3f-00f1-8938-2eebd82ab676">
               <id root="d3d3cb52-6062-9b25-537d-1dff95612699"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>80 mg: 100's Carton Label</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM692781031621"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250225"/>
            </section>
         </component>
      </structuredBody>
   </component>
</document>